[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15002
1. Wang CC, Lin YC, Wang SS, Shih C, Lin YH, Tung CW: SkinSensDB: a curated database for skin sensitization assays. J Cheminform; 2017;9:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SkinSensDB: a curated database for skin sensitization assays.
  • : Skin sensitization is an important toxicological endpoint for chemical hazard determination and safety assessment.
  • Prediction of chemical skin sensitizer had traditionally relied on data from rodent models.
  • The development of the adverse outcome pathway (AOP) and associated alternative in vitro assays have reshaped the assessment of skin sensitizers.
  • Current computational models to predict skin sensitization mainly based on in vivo assays without incorporating alternative in vitro assays.
  • However, there are few freely available databases integrating both the in vivo and the in vitro skin sensitization assays for development of AOP-based skin sensitization prediction models.
  • To facilitate the development of AOP-based prediction models, a skin sensitization database named SkinSensDB has been constructed by curating data from published AOP-related assays.
  • In addition to providing datasets for developing computational models, SkinSensDB is equipped with browsing and search tools which enable the assessment of new compounds for their skin sensitization potentials based on data from structurally similar compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28194231.001).
  • [Journal-full-title] Journal of cheminformatics
  • [ISO-abbreviation] J Cheminform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N: Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. Trials; 2017 Mar 07;18(1):111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
  • Whole genome molecular profiling experiments led to the discovery of an attractive molecular target in these skin tumour cells, named tropomyosin receptor kinase (TRK), upon which these cells demonstrate an oncogenic dependency in preclinical studies.
  • Recently, the development of an ointment containing a TRK inhibitor (pegcantratinib - previously CT327 - from Creabilis SA) allowed for the assessment of TRK inhibition in tumours from patients with inherited CYLD mutations.
  • Cohort 1 will determine the safety and acceptability of applying pegcantratinib for 4 weeks to a single tumour on a CYLD mutation carrier that is scheduled for a routine lesion excision (n = 8 patients).
  • DISCUSSION: Interventions for rare genetic skin diseases are often difficult to assess in an unbiased way due to small patient numbers and the challenges of incorporating adequate controls into trial design.
  • Here we present a single-centre, randomised, placebo-controlled trial design that leverages the multiplicity of tumours seen in an inherited skin tumour syndrome that may inform the design of other studies in similar genetic diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):5962-7 [19755385.001]
  • [Cites] Stat Med. 2001 Mar 30;20(6):859-66 [11252008.001]
  • [Cites] Expert Opin Investig Drugs. 2010 Mar;19(3):427-36 [20141349.001]
  • [Cites] Acta Derm Venereol. 2015 May;95(5):542-8 [25594427.001]
  • [Cites] Lancet Oncol. 2015 Sep;16(9):e460-9 [26370355.001]
  • [Cites] Oncogene. 2013 Aug 8;32(32):3698-710 [23027130.001]
  • [Cites] N Engl J Med. 2012 Jun 7;366(23 ):2180-8 [22670904.001]
  • [Cites] Oncogene. 2011 Oct 13;30(41):4243-60 [21552290.001]
  • [Cites] Arch Dermatol. 2009 Nov;145(11):1277-84 [19917957.001]
  • [Cites] J Invest Dermatol. 2011 Aug;131(8):1735-44 [21430703.001]
  • [Cites] Carcinogenesis. 2010 Nov;31(11):1939-47 [20802235.001]
  • (PMID = 28270164.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; CYLD / CYLD defective tumours / Cylindromatosis / Pegcantratinib / TRK inhibition / Tropomyosin receptor kinase (TRK) inhibitor
  •  go-up   go-down


3. Jiz II MAL, Mingala CN, Lopez IFM, Chua M, Gabonada FG Jr, Acosta LP, Wu H, Kurtis JD: A field trial of recombinant Schistosoma japonicum paramyosin as a potential vaccine in naturally-infected water buffaloes. Ann Parasitol; 2016;62(4):295-299
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall aims of this project are to assess the safety and immunogenicity of the Schistosoma japonicum vaccine paramyosin among water buffaloes residing in endemic areas.
  • The safety trial involved the first 20 animals and included skin testing, vaccination, anaphylaxis monitoring, as well as hematology and serum chemistry analysis.
  • Skin tests revealed that only three out of 20 animals exhibited redness at the injection site, with none greater than 1 cm.
  • Immunogenicity assessment of sera collected prior to every vaccination and one month after the last dose showed that the paramyosin vaccine induced robust antibody responses to all animals, as assessed by ELISA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28158940.001).
  • [ISSN] 2299-0631
  • [Journal-full-title] Annals of parasitology
  • [ISO-abbreviation] Ann Parasitol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
4. Frederick DM, Vorwerk L, Gupta A, Ghassemi A: Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin. Cutan Ocul Toxicol; 2017 Jan 11;:1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin.
  • CONTEXT: The prevalence of sensitive skin among the general population in industrialized countries is reported to be over 50%.
  • Sensitive skin subjects often report significant reactions to contact with cosmetics, soaps and other consumer products.
  • OBJECTIVE: This paper describes the overall skin compatibility and mildness program for a newly developed, lightly fragranced, colorant free laundry product (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent), specially formulated for individuals with sensitive skin.
  • The skin mildness of the product was compared to Arm & Hammer™ Free & Clear liquid laundry detergent with no fragrance or colorant, and an established history of safe use by sensitive skin consumers.
  • MATERIALS AND METHODS: The test material was a liquid laundry product with a light scent formulated for sensitive skin consumers (Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent).
  • The product was compared to commercially marketed products for sensitive skin with a history of skin safety in the marketplace, including: a very similar product formulation (Arm & Hammer™ Free & Clear with no fragrance), and several selected competitors' products.
  • Studies were conducted among individuals with self-assessed sensitive skin (based on a questionnaire) using standard protocols for the Human Repeat Insult Patch Test (HRIPT), 10-Day Cumulative Irritation, the Wrist Band Wear test, and the Safety In-Use testing.
  • RESULTS: The HRIPT confirmed that neither the fragrance alone, nor the product formulation with fragrance, induced contact sensitization in sensitive skin subjects.
  • The 10-Day cumulative irritation study conducted using sensitive skin subjects showed highly favorable skin compatibility, and the test product was comparable to the control product (Arm & Hammer Free & Clear) and other nonirritant controls.
  • In the Wrist Band Wear test, exposure to laundered fabrics under exaggerated conditions gave similar results for the test and control products, with no objective signs of skin irritation, and no self-reported persistent adverse sensory effects.
  • The Safety In-Use tests evaluated 4-week exposure to product and laundered fabrics under realistic use conditions.
  • There were no clinically objective signs of skin irritation, and reports of transitory, mild sensory effects were minimal and similar for the test and controls.
  • DISCUSSION AND CONCLUSION: A comprehensive skin safety program on a lightly scented sensitive skin laundry formulation (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent) conducted among panels of self-assessed sensitive skin subjects demonstrated that the presence of a light fragrance did not adversely impact skin compatibility in any of the testing protocols when the product was compared to a similar product with no fragrance.
  • The lightly fragranced product demonstrated overall skin compatibility and mildness when tested in a self-assessed sensitive skin population, and compared favorably to currently marketed sensitive skin products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28073339.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Consumer product safety / contact sensitization / cumulative irritation / safety in use test / sensitive skin / skin irritation / wrist band test
  •  go-up   go-down


5. Jiang Y, Zhang X, Lu Z, Gold MH: Assessment of efficacy and safety of a fractionated bipolar radiofrequency device for the treatment of lower face wrinkles and laxity. J Cosmet Laser Ther; 2016 Dec 21;:1-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of efficacy and safety of a fractionated bipolar radiofrequency device for the treatment of lower face wrinkles and laxity.
  • : Skin aging, as a natural course, is a gradual process.
  • Fractional bipolar RF as a novel means of rejuvenation has been used in clinical practice, but questions remain in terms of its efficacy and safety.
  • Considering a large population in our country and huge demands for skin tightening, we did this research to evaluate the efficacy and safety of fractional bipolar radiofrequency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001455.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; MFWS / bipolar fractionated radiofrequency / skin laxity / wrinkle treatment
  •  go-up   go-down


6. Goebel C, Aeby P, Ade N, Alépée N, Aptula A, Araki D, Dufour E, Gilmour N, Hibatallah J, Keller D, Kern P, Kirst A, Marrec-Fairley M, Maxwell G, Rowland J, Safford B, Schellauf F, Schepky A, Seaman C, Teichert T, Tessier N, Teissier S, Weltzien HU, Winkler P, Scheel J: Guiding principles for the implementation of non-animal safety assessment approaches for cosmetics: skin sensitisation. Regul Toxicol Pharmacol; 2012 Jun;63(1):40-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guiding principles for the implementation of non-animal safety assessment approaches for cosmetics: skin sensitisation.
  • Characterisation of skin sensitisation potential is a key endpoint for the safety assessment of cosmetic ingredients especially when significant dermal exposure to an ingredient is expected.
  • COLIPA (the European Cosmetics Association) funds an extensive programme of skin sensitisation research, method development and method evaluation and helped coordinate the early evaluation of the three test methods currently undergoing pre-validation.
  • In May 2010, a COLIPA scientific meeting was held to analyse to what extent skin sensitisation safety assessments for cosmetic ingredients can be made in the absence of animal data.
  • In order to propose guiding principles for the application and further development of non-animal safety assessment strategies it was evaluated how and when non-animal test methods, predictions based on physico-chemical properties (including in silico tools), threshold concepts and weight-of-evidence based hazard characterisation could be used to enable safety decisions.
  • Generation and assessment of potency information from alternative tools which at present is predominantly derived from the LLNA is considered the future key research area.
  • [MeSH-major] Allergens / toxicity. Animal Testing Alternatives. Consumer Product Safety. Cosmetics / toxicity. Hypersensitivity / etiology. Skin / drug effects
  • [MeSH-minor] Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Allergy.
  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier Inc. All rights reserved.
  • (PMID = 22374415.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Allergens; 0 / Cosmetics
  •  go-up   go-down


7. Jafferany M, Osuagwu FC: Use of Topiramate in Skin-Picking Disorder: A Pilot Study. Prim Care Companion CNS Disord; 2017 Jan 26;19(1)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Topiramate in Skin-Picking Disorder: A Pilot Study.
  • Objective: Repetitive skin picking that culminates in skin lesions and excoriations has a fairly common prevalence and causes clinically significant distress.
  • Methods: Ten patients (8 women and 2 men) with skin-picking disorder (per DSM-5 criteria) were enrolled in the study.
  • Different measures to evaluate the efficacy of topiramate included subjective and objective assessment, photographs, the Skin Picking Scale modified after the Yale-Brown Obsessive-Compulsive Scale (SPS-Y-BOCS), the Skin Picking Impact Scale, the Clinical Global Impressions-Improvement (CGI-I) and CGI-Severity scales, and the Beck Anxiety Inventory and Beck Depression Inventory.
  • Results: Topiramate improved time spent skin picking from 85 minutes to 30 minutes per day.
  • The scores on the Skin Picking Impact Scale and SPS-Y-BOCS also improved.
  • Anxiety and depression symptoms improved after reduction in skin-picking symptoms (the Beck Anxiety Inventory score improved from a mean of 38.8 to 13.8 and the Beck Depression Inventory score from 28.9 to 10.1).
  • Conclusions: Topiramate appears to be a promising agent in the treatment of skin-picking symptoms.
  • Double-blind controlled trials are needed to further evaluate the safety and efficacy of topiramate in larger population samples.
  • [MeSH-minor] Adolescent. Adult. Anxiety / epidemiology. Depression / epidemiology. Female. Humans. Male. Pilot Projects. Psychiatric Status Rating Scales. Severity of Illness Index. Skin / pathology. Socioeconomic Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28129492.001).
  • [ISSN] 2155-7780
  • [Journal-full-title] The primary care companion for CNS disorders
  • [ISO-abbreviation] Prim Care Companion CNS Disord
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Psychotropic Drugs; 0H73WJJ391 / topiramate; 30237-26-4 / Fructose
  •  go-up   go-down


8. Kolumam G, Wu X, Lee WP, Hackney JA, Zavala-Solorio J, Gandham V, Danilenko DM, Arora P, Wang X, Ouyang W: IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice. PLoS One; 2017;12(1):e0170639
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mechanistically, when compared to other growth factors such as VEGF and PDGF that accelerate wound healing in this model, IL-22 uniquely induced genes involved in reepithelialization, tissue remodeling and innate host defense mechanisms from wounded skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Jan 12;104(1):9-19 [11163236.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Cytokine. 2013 Jun;62(3):360-8 [23582717.001]
  • [Cites] J Invest Dermatol. 2012 Jun;132(6):1717-24 [22358061.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):1080-7 [16936280.001]
  • [Cites] J Invest Dermatol. 2015 Nov;135(11):2862-70 [26168231.001]
  • [Cites] Biologics. 2008 Mar;2(1):1-12 [19707423.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3545-9 [11564763.001]
  • [Cites] Nat Rev Immunol. 2014 Dec;14(12):783-95 [25421700.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Am J Surg. 1998 Aug;176(2A Suppl):48S-54S [9777972.001]
  • [Cites] Sci Transl Med. 2014 Feb 12;6(223):223ra22 [24523322.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1545-51 [12737879.001]
  • [Cites] Nature. 2014 Oct 9;514(7521):237-41 [25119041.001]
  • [Cites] Wound Repair Regen. 2007 Sep-Oct;15(5):665-70 [17971012.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1235-46 [2356856.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7341-7 [11706020.001]
  • [Cites] BMC Microbiol. 2008 Mar 06;8:43 [18325110.001]
  • [Cites] Nat Immunol. 2011 Aug 28;12(10):941-8 [21874025.001]
  • [Cites] Organogenesis. 2011 Jul-Sep;7(3):202-8 [22041517.001]
  • [Cites] Sci Transl Med. 2011 Dec 14;3(113):113ra126 [22174314.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47517-23 [12351624.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1736-43 [16291068.001]
  • [Cites] World J Diabetes. 2014 Aug 15;5(4):546-56 [25126400.001]
  • [Cites] Surgeon. 2007 Aug;5(4):219-31 [17849958.001]
  • [Cites] Front Biosci. 2004 Jan 01;9:283-9 [14766366.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31335-9 [10875937.001]
  • [Cites] Nat Med. 2008 Mar;14(3):275-81 [18264110.001]
  • [Cites] J Invest Dermatol. 2013 May;133(5):1321-9 [23223145.001]
  • [Cites] Nat Med. 2008 Mar;14(3):282-9 [18264109.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1219-22 [17476353.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1719-24 [16291066.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):835-70 [12843410.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):234-44 [10951241.001]
  • [Cites] Wound Repair Regen. 2004 Jul-Aug;12(4):485-92 [15260814.001]
  • [Cites] Clin Dermatol. 2007 Jan-Feb;25(1):9-18 [17276196.001]
  • [Cites] Bioinformatics. 2007 Jan 15;23(2):257-8 [17098774.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):1935-47 [15161630.001]
  • [Cites] J Biomed Biotechnol. 2011;2011:969618 [21151647.001]
  • [Cites] World J Diabetes. 2015 Feb 15;6(1):37-53 [25685277.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1725-35 [16291067.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2229-40 [17277128.001]
  • [Cites] Clin Plast Surg. 2003 Jan;30(1):1-12 [12636211.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3695-702 [15749908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 25;107(21):9546-51 [20460310.001]
  • [Cites] Wound Repair Regen. 2008 Sep-Oct;16(5):585-601 [19128254.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1309-23 [16619290.001]
  • [Cites] Immunity. 2008 Apr;28(4):454-67 [18400188.001]
  • (PMID = 28125663.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Hojerová J, Peráčková Z, Beránková M: Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication. Food Chem Toxicol; 2017 May;103:66-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication.
  • Sunscreens are intended to work on the skin.
  • The potential for systemic absorption of Benzophenone-3 (BP3, 10%) and Ethylhexyl Triazone (EHT, 5%) in a silicone-based water-in-oil emulsion was assessed in vitro using a full-thickness porcine-ear skin mimicking in-use conditions.
  • (ii) on the whole-body skin, was (i) 136 and 30;.
  • Skin shaving increased BP3 and EHT bioavailability 1.38 and 1.80-fold, respectively.
  • Margin of Safety values were estimated according to guidelines applicable for European Union.
  • For three realistic exposure scenarios, MoS of 48, 34 and 34 for BP3 in the sunscreen applied on the whole-body indicate some concerns regarding the safety for consumers (MoS<100).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28216167.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Benzophenone-3 / Ethylhexyl triazone / Human exposure assessment / Margin of safety / Shaving skin / Systemic exposure dose
  •  go-up   go-down


10. Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N: Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf; 2017 Apr;40(4):317-331
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
  • METHODS: A retrospective analysis of public Facebook and Twitter data was conducted for 10 recent FDA postmarketing safety signals at the drug-event pair level with six negative controls.
  • Drug safety physicians conducted a manual review to determine causality using World Health Organization-Uppsala Monitoring Centre (WHO-UMC) assessment criteria.
  • Of these, 13 posts were selected for causality assessment of product-event pairs.
  • Clinical assessment revealed that posts had sufficient information to warrant further investigation for two possible product-event associations: dronedarone-vasculitis and Banana Boat Sunscreen--skin burns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Drug Saf. 2015;14(12):1845-53 [26436834.001]
  • [Cites] J Biomed Inform. 2015 Jun;55:73-81 [25817970.001]
  • [Cites] Patient Prefer Adherence. 2015 Jan 23;9:173-84 [25670886.001]
  • [Cites] Drug Saf. 2014 Oct;37(10):761-4 [25096955.001]
  • [Cites] J Med Internet Res. 2015 Jul 10;17(7):e171 [26163365.001]
  • [Cites] J Biomed Inform. 2016 Feb;59:42-8 [26610385.001]
  • [Cites] Nat Rev Rheumatol. 2015 Feb;11(2):119-23 [25314016.001]
  • [Cites] J Biomed Inform. 2011 Dec;44(6):989-96 [21820083.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1161-6 [17486665.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):256-62 [23322591.001]
  • [Cites] J Am Board Fam Pract. 2004 Mar-Apr;17(2):142-9 [15082674.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:202-12 [25720841.001]
  • [Cites] J Clin Pharm Ther. 2014 Feb;39(1):53-5 [24304185.001]
  • [Cites] Drug Saf. 2011 Apr 1;34(4):267-71 [21417499.001]
  • [Cites] Methods Inf Med. 2013;52(2):152-9 [23450374.001]
  • [Cites] Drug Saf. 2016 May;39(5):443-54 [26798054.001]
  • [Cites] Eur J Clin Pharmacol. 2013 Feb;69(2):209-15 [22688722.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):239-46 [24713590.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):910-20 [26147850.001]
  • [Cites] Drug Saf. 2014 Aug;37(8):629-37 [25027671.001]
  • [Cites] Adv Psychobiol. 1974;2:297-312 [4476178.001]
  • [Cites] N Z Med J. 2014 Aug 29;127(1401):69-81 [25225758.001]
  • [Cites] Drug Saf. 2014 May;37(5):343-50 [24777653.001]
  • [Cites] J Biomed Inform. 2015 Feb;53:196-207 [25451103.001]
  • [Cites] J Med Internet Res. 2007 Feb 28;9(1):e4 [17478413.001]
  • [Cites] J Med Internet Res. 2011 May 17;13(2):e37 [21586386.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2153-5, 2157 [19423867.001]
  • [Cites] J Addict Dis. 2015;34(4):303-10 [26364675.001]
  • [Cites] Br J Clin Pharmacol. 1996 Oct;42(4):423-9 [8904613.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):878-88 [26271492.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:230-40 [25688695.001]
  • [Cites] J Am Med Inform Assoc. 2015 May;22(3):671-81 [25755127.001]
  • [Cites] Drug Saf. 1999 Feb;20(2):95-107 [10082068.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):149-50 [25056395.001]
  • [Cites] Drug Saf. 2015 Oct;38(10):921-30 [26242616.001]
  • [Cites] Res Social Adm Pharm. 2014 Nov-Dec;10(6):896-903 [24603135.001]
  • [Cites] Trends Pharmacol Sci. 2013 Jul;34(7):357-8 [23759353.001]
  • [Cites] J Antimicrob Chemother. 2014 Sep;69(9):2568-72 [24862092.001]
  • [Cites] AMIA Annu Symp Proc. 2014 Nov 14;2014:924-33 [25954400.001]
  • [Cites] J Nerv Ment Dis. 1972 Nov;155(5):363-5 [5082173.001]
  • (PMID = 28044249.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


11. Wohlrab J, Gilbrich F, Wolff L, Fischer M, Philipp S: [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch]. Hautarzt; 2016 Dec 15;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].
  • OBJECTIVES: For lack of clinical safety data, preclinical tests for cutaneous cytotoxicity and calculations for systemic bioavailability after topical application have been performed.
  • CONCLUSION: The present data cannot fully remove safety concerns for topical application of chloral hydrate in the formulation favoured by the NRF (Neues Rezepturformularium)-the so-called 1‑2-3-cream.
  • For a better assessment of harmlessness, tests for cutaneous bioavailability (concentration-time profile) on human skin and clinical studies would be necessary.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27981385.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Journal Article; English Abstract
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Administration / Antipruritics / Bioavailability / Cytotoxicity / Psoriasis
  •  go-up   go-down


12. Nam CH, Park BC, Kim MH, Choi EH, Hong SP: The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles. Dermatol Surg; 2017 Feb 09;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles.
  • BACKGROUND: Low-level light therapy (LLLT) using light-emitting diodes (LEDs) is considered to be helpful for skin regeneration and anti-inflammation.
  • OBJECTIVE: To evaluate the efficacy and safety of 2 types of LLLTs using 660 nm-emitting red LEDs and 411 to 777 nm-emitting white LEDs in the treatment of facial wrinkles.
  • RESULTS: In both groups treated with red and white LEDs, the wrinkle measurement from skin replica improved significantly from baseline at Week 12.
  • In the global assessment of the subjects, the mean improvement score of the red LED group was higher than that of the white LED group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28195844.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Attia A, Abushouk AI, Ahmed H, Gadelkarim M, Elgebaly A, Hassan Z, Abdel-Daim MM, Negida A: Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Clin Drug Investig; 2017 May;37(5):439-451
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
  • BACKGROUND: Psoriasis is an inflammatory skin disease that affects 2-3% of the worldwide population.
  • We aimed to evaluate the safety and efficacy of brodalumab as a therapeutic agent for moderate-to-severe psoriasis in a meta-analysis framework.
  • Analysis of secondary outcomes showed that brodalumab was superior to placebo in terms of static physician's global assessment (RR = 32.53, 95% CI 13.80-76.69) and psoriasis symptoms inventory scores (RR = 14.70, 95% CI 8.38-25.78).
  • CONCLUSION: Brodalumab showed an acceptable safety profile and a robust efficacy in the treatment of moderate-to-severe plaque psoriasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197901.001).
  • [ISSN] 1179-1918
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  •  go-up   go-down


14. Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R: A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol; 2017 Jan 20;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
  • BACKGROUND: Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases.
  • OBJECTIVES: The primary objective was to evaluate cutaneous safety and tolerability of AVX001 in doses from 0.002% to 5.0%.
  • Safety was assessed as local skin reaction adverse events (LSRAE) grades 3-4.
  • The secondary objective was assessment of efficacy on modified PASI (mPASI) score compared with placebo.
  • The treatment period was four weeks with two-week follow-up with assessment at screening, randomization and once weekly until study end.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107559.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Munavalli G: A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients. J Drugs Dermatol; 2016 Nov 01;15(11):1335-1342
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients.
  • : Recent appreciation of the multifactorial pathophysiology of skin aging has led to increased use of parallel treatment regimens.
  • This prospective, split-face, randomized study assessed the safety and efficacy of same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST) facial rejuvenation treatment in comparison to fractional non-ablative laser (NAFL) treatment only.
  • Immediate skin responses were assessed within 30 minutes of treatment, while wrinkle/elastosis scores, and skin tone and texture were evaluated 1, 3, and 6 months following the final treatment session.
  • Physician-evaluated skin tone and patient ratings of skin texture and overall improvement of the SST-treated side were consistently higher than the contralateral NAFL-treated side.
  • Although the SST regimen failed to demonstrate statistically signi cant clinical superiority over the NAFL regimen, the significantly lower pain levels, consistently higher physician and patient ratings following SST may justify its regular use as a skin rejuvenation technique.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095544.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Petry T, Bosch A, Coste X, Eigler D, Germain P, Seidel S, Jean PA: Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes. Regul Toxicol Pharmacol; 2017 Mar;84:64-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes.
  • The skin sensitization potential of chemicals has traditionally been evaluated in vivo according to OECD testing guidelines in guinea pigs or the mouse local lymph node assay.
  • There has lately been a great emphasis on establishing in vitro test methods reflecting the key biological events in the adverse outcome pathway (AOP) for skin sensitization as published by the OECD.
  • Against this background, a group of 8 polysiloxanes and silanes, seven of them aminofunctionalised, for which in vivo data were already available, has been tested in vitro in the direct peptide reactivity assay (DPRA), the KeratinoSens™ and the human cell line activation test (h-CLAT) and in the modified myeloid U937 skin sensitization test (mMUSST) as far as technically feasible.
  • The data also allow for a preliminary evaluation of proposed integrated testing strategies (ITS) to determine the skin sensitization potential of chemicals which were not considered in the training sets of the respective ITS.
  • [MeSH-major] Biological Assay. Dendritic Cells / drug effects. Dermatitis, Allergic Contact / etiology. Irritants / toxicity. Keratinocytes / drug effects. Silanes / toxicity. Siloxanes / toxicity. Skin Irritancy Tests / methods
  • [MeSH-minor] Animal Testing Alternatives. Animals. Feasibility Studies. Gene Expression Regulation / drug effects. Genes, Reporter. Guinea Pigs. Humans. Local Lymph Node Assay. Mice, Inbred CBA. Risk Assessment. U937 Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28017767.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Irritants; 0 / Silanes; 0 / Siloxanes
  • [Keywords] NOTNLM ; DPRA (major topic) / GPMT (major topic) / In vitro (major topic) / KeratinoSens™ (major topic) / LLNA (major topic) / Polysiloxanes (major topic) / Sensitization (major topic) / Silanes (major topic) / h-CLAT (major topic) / mMUSST (major topic)
  •  go-up   go-down


17. Lv R, Sun Q: A Network Meta-analysis of Non-melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment. J Cell Biochem; 2017 Mar 29;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Network Meta-analysis of Non-melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment.
  • The mainstream treatments for non-melanoma skin cancer (NMSC) include photodynamic therapy (PDT), surgery excision (SE), cryotherapy (CT), imiquimod (IM), radiotherapy (RT), 5-fluorouracil (FU) and vehicle (VE).
  • Our network meta-analysis (NMA) was aimed at evaluating the efficacy and safety of these seven treatments and providing superior ones.
  • The SUCRA results indicated that SE was the treatment with best ranking in the entire three efficacy indexes and a relatively high safety.
  • Taking efficacy and safety into account, our study recommended SE as the optimal regimen for NMSC with high efficacy considering CLR, CLC and CRP and moderate AEs when compared with other interventions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28370183.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; efficacy / network meta-analysis / non-melanoma skin cancer treatments / safety
  •  go-up   go-down


18. Sharma AD, Julka PK, Rastogi A, Suri T, Rath GK, Sharma BN, Baliga VP: Assessment of efficacy, safety, and tolerability of aprepitant in adult patients with chemotherapy-induced vomiting. J Clin Oncol; 2009 May 20;27(15_suppl):e20729
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of efficacy, safety, and tolerability of aprepitant in adult patients with chemotherapy-induced vomiting.
  • The present study was undertaken to assess efficacy, safety, and tolerability of Aprepitant in adult patients with chemotherapy induced nausea and vomiting.
  • Self assessment of nausea was done by patients using a 100 mm visual analog scale.
  • Safety and tolerability was assessed through monitoring of adverse events and physical examination.
  • Overall global assessment of vomiting indicated that 19 patients (82.6 %) had very good improvement, 3 patients (13%) had good improvement and one patient (4.4%) showed fair improvement after treatment with aprepitant.
  • The most common adverse events included fever, headache, diarrhoea skin rash, constipation, and blisters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL: A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):3179
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.
  • This phase I monotherapy study evaluated safety, tolerability, and PK in patients with advanced solid tumors at once (QD) and twice daily (BID) dosing schedules.
  • RESULTS: 81 pts with various carcinomas were enrolled; 64 pts (39 QD, 25 BID) included in safety and disease assessment; 57 included in PK.
  • There were no clinically significant changes in the other safety evaluations.
  • The majority of AEs were grade 1 or 2 skin and/or GI toxicities, manageable with symptomatic treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Xiong J, Chiu Y, Pradhan RS, Li X, Li X, Carlson DM, Awni W: Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e13082
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer.
  • The aim of this assessment was to evaluate the impact of ethnicity on linifanib tolerability and pharmacokinetics (PK) in cancer patients.
  • The impact of ethnicity on tolerability was assessed by evaluating significance of ethnicity on the exposure-safety relationship.
  • Logistic regression analysis was conducted to construct the exposure-safety relationship for eight common adverse events (hypertension, asthenia, GI-abdominal disorder, diarrhea, skin toxicity 1, skin toxicity 2, proteinuria and anorexia).
  • RESULTS: The exposure-safety response analysis showed that ethnicity was not a significant factor influencing the exposure-safety response relationship for any of the tested adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Cameli N, Mariano M, Cordone I, Abril E, Masi S, Foddai ML: Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment. Dermatol Surg; 2017 Apr 03;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment.
  • BACKGROUND: Platelet-rich plasma (PRP) is an emerging treatment in dermatology recently proposed for skin rejuvenation.
  • OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.
  • RESULTS: Clinical and patient evaluation showed improvement of skin texture.
  • Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved.
  • CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28375975.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Redley B, Raggatt M: Use of standard risk screening and assessment forms to prevent harm to older people in Australian hospitals: a mixed methods study. BMJ Qual Saf; 2017 Mar 13;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of standard risk screening and assessment forms to prevent harm to older people in Australian hospitals: a mixed methods study.
  • BACKGROUND: Standard risk screening and assessment forms are frequently used in strategies to prevent harm to older people in hospitals.
  • (1) cross-sectional audit of the standard risk screening and assessment forms used to assess older people at 11 health services in 2015;.
  • RESULTS: 152 standard assessment forms from 11 Victorian health services included over 3700 items with 17% duplicated across multiple forms.
  • Assessments of skin integrity and mobility loss (including falls) were consistently included in forms; however, nutrition, cognitive state, pain and medication risks were inconsistent; and continence, venous thromboembolism risk and hospital acquired infection from invasive devices were infrequent.
  • Qualitative analyses revealed five themes explaining issues associated with current use of assessment forms:.
  • (1) comprehensive assessment of preventable harms;.
  • CONCLUSIONS: Current use of standard risk screening and assessment forms is associated with a high burden and gaps in assessment of several common preventable harms that can increase risk to older people in hospital.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
  • (PMID = 28289243.001).
  • [ISSN] 2044-5423
  • [Journal-full-title] BMJ quality & safety
  • [ISO-abbreviation] BMJ Qual Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Health services research / Healthcare quality improvement / Patient safety / Risk management
  •  go-up   go-down


23. Watzek N, Berger F, Kolle SN, Kaufmann T, Becker M, van Ravenzwaay B: Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results. Regul Toxicol Pharmacol; 2017 Apr;85:25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results.
  • In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation.
  • This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used.
  • Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28159477.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Allergens; 0 / Cyclohexylamines; 0 / Excipients; 0 / Haptens; 0 / Olive Oil; 1364PS73AF / Acetone; 6DC9Q167V3 / Propylene Glycol
  • [Keywords] NOTNLM ; AOO / Adverse Outcome Pathway / BrdU-ELISA / False positive results / Local Lymph Node Assay / Skin sensitization / Test substance stability in the vehicle
  •  go-up   go-down


24. Janne PA, Reckamp K, Koczywas M, Engelman JA, Camidge DR, Rajan A, Khuri F, Liang JQ, O'Connell J, Giaccone G: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):8063
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial.
  • Endpoints include objective response rate, duration of response, progression-free survival, survival, safety/tolerability, and pharmacokinetics.
  • Pharmacodynamic endpoints include assessment of serum levels of HER2 and EGFR extracellular domains.
  • The most common treatment-related AEs were skin and gastrointestinal disorders, with grade 3 AEs in 19% and 13% of pts, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962636.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Dentan C, Forestier E, Roustit M, Boisset S, Chanoine S, Epaulard O, Pavese P: Assessment of linezolid prescriptions in three French hospitals. Eur J Clin Microbiol Infect Dis; 2017 Jan 26;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of linezolid prescriptions in three French hospitals.
  • Linezolid is approved in pneumonia and complicated skin and soft tissue infections.
  • Educational programs are mandatory to improve practices, as well as clinical studies to better assess the efficacy and safety of linezolid in clinical situations other than pneumonia or complicated skin and soft tissue infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28127641.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Lai PM, Collaku A, Reed K: Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial. J Int Med Res; 2017 Apr;45(2):647-661
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial.
  • Secondary outcomes included pain relief (PR); PI; time to onset of PR, meaningful PR, cooling, and complete recovery; PI difference; sum of PI difference; total PR; reduction in ankle swelling; and the patient's global assessment of response to treatment.
  • There was a higher incidence of skin and application-site events with 1% diclofenac/3% menthol than with placebo or 1% diclofenac.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28345425.001).
  • [ISSN] 1473-2300
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ankle sprain / diclofenac / menthol / pain / topical administration
  •  go-up   go-down


27. Makino ET, Kadoya K, Sigler ML, Hino PD, Mehta RC: Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations. J Drugs Dermatol; 2016 Dec 01;15(12):1562-1570
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.
  • OBJECTIVES: To develop a comprehensive product (LYT2) that affects all major biological pathways controlling pigmentation and test for clinical efficacy and safety in different ethnic populations.
  • METHODS: A thorough analysis of biological pathways was used to identify ingredient combinations for LYT2 that provided optimal melanin reduction in a 3-D skin model.
  • The outcome clearly shows greater pigmentation control with LYT2 compared to other HQ-free products in skin tissue models and earlier control in clinical studies compared to 4% HQ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095579.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC: A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technol Assess; 2017 Mar;21(10):1-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
  • BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity and mortality in the elderly.
  • OBJECTIVES: To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP treatment with oral doxycycline or oral prednisolone.
  • We hypothesised that starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral prednisolone.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28406394.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Scotte F, Tourani JM, Banu E, Peyromaure M, Jenabian A, Levy E, Coquelin K, Magherini E, Marsan S, Oudard S: Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. J Clin Oncol; 2004 Jul 15;22(14_suppl):8003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study.
  • : 8003 Background: Onycholysis and skin toxicity occur in about 15% of patients (pts) treated with docetaxel (D).
  • We investigated the efficacy and safety of an Elasto-Gel (Akromed, France) flexible frozen glove (FG) for the prevention of D-induced onycholysis and skin toxicity.
  • Onycholysis and skin toxicity were assessed at each cycle by NCI-CTC v.2 criteria and documented by photography.
  • Onycholysis and skin toxicity (main criteria) was significantly lower in the FG protected hand compared with the control hand (p=0.0001, Wilcoxon test).
  • Skin toxicity was G0: 73% vs. 41% and G1-2: 27% vs. 59% in the FG-protected hand and the control hand, respectively.
  • Median time to nail and skin toxicity occurrence was not significantly different between FG-protected and the control hand, respectively [106 days (5 cycles) vs. 58 days (2.7 cycles) for nail toxicity; 57 days vs. 58 days for skin toxicity].
  • CONCLUSIONS: Frozen glove significant reduces the nail and skin toxicity associated with docetaxel and provides a new tool in supportive care management for a better patient's quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Thiesen LC, Baccarin T, Fischer-Muller AF, Meyre-Silva C, Couto AG, Bresolin TM, Santin JR: Photochemoprotective effects against UVA and UVB irradiation and photosafety assessment of Litchi chinensis leaves extract. J Photochem Photobiol B; 2017 Feb;167:200-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photochemoprotective effects against UVA and UVB irradiation and photosafety assessment of Litchi chinensis leaves extract.
  • Actually, there has been an increase in the use of natural products as skin photoprotective agents.
  • Data herein obtained pointed out the potential of L. chinensis extract for photochemoprotection against UVA/UVB radiation and its damaging effects on human skin.
  • [MeSH-major] DNA Damage / drug effects. Litchi / chemistry. Plant Extracts / pharmacology. Plant Leaves / chemistry. Safety. Ultraviolet Rays

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28086120.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Plant Extracts; BBX060AN9V / Hydrogen Peroxide
  • [Keywords] NOTNLM ; Irritant / Litchi chinensis / Photochemoprotection / Photohaemolysis / Phototoxicity
  •  go-up   go-down


31. Agarwala SS, Thompson J, Smithers M, Ross M, Coventry B, Minor D, Scoggins C, Hersey P, Wachter E: Chemoablation of melanoma with intralesional rose bengal (PV-10). J Clin Oncol; 2009 May 20;27(15_suppl):9060
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An additional 1-2 lesions, including visceral lesions, remain untreated for assessment of bystander response.
  • A modified Fleming design allows interim assessment of safety and OR at weeks 4 and 24, respectively, after treatment of the 20<sup>th</sup> and 40<sup>th</sup> subjects.
  • RESULTS: Interim safety data for the first 40 subjects treated is comparable to phase 1, with transient mild to moderate locoregional pain, vesicles or edema most common; Grade 3 AEs have been rare (1 case each of vesicles and skin flap necrosis), with no Grade 4 or 5 AEs attributed to PV-10.
  • CONCLUSIONS: The safety and efficacy profile of intralesional therapy with PV-10 compares favorably with available therapeutic options for this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962145.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Conrad B, Harbeck N, Von Minckwitz G, Wuellner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Loibl S, GBG/AGO-B study groups: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). J Clin Oncol; 2011 May 20;29(15_suppl):1059
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary objective was the rate of pCR at time of surgery; main secondary objectives were the assessment of safety and clinical response.
  • The following grade 1-4 toxicities were reported in pt: hand-foot syndrome (HFS) 4, other skin reactions 2, diarrhea 2, mucositis 1, hypertension 1, 7/12 pts discontinued early, due to AEs 5, progressive disease 2.
  • Toxicities grade 1-4: HFS 6, other skin reactions 7, diarrhea 2, mucositis 1.
  • No patients stopped due to skin toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020666.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Gawdat HI, Tawdy AM, Hegazy RA, Zakaria MM, Allam RS: Autologous platelet-rich plasma versus readymade growth factors in skin rejuvenation: A split face study. J Cosmet Dermatol; 2017 Apr 05;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous platelet-rich plasma versus readymade growth factors in skin rejuvenation: A split face study.
  • BACKGROUND: The escalating urge for a youthful-looking skin instigates continuous innovations with minimally invasive procedures.
  • OBJECTIVE: Compare the efficacy and safety of PRP to readymade growth factors in skin rejuvenation.
  • PATIENTS AND METHODS: Twenty adult females with Fitzpatrick skin types III-IV and Glogau photoaging types II and III were enrolled in this study.
  • RESULTS: Both procedures yielded significant improvement regarding both GAIS (skin turgor and overall vitality) and OCT (epidermal and dermal thickness) assessment.
  • CONCLUSION: Platelet-rich plasma is effective and safe for skin rejuvenation, comparable to readymade growth factors with noticeable higher longevity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28382785.001).
  • [ISSN] 1473-2165
  • [Journal-full-title] Journal of cosmetic dermatology
  • [ISO-abbreviation] J Cosmet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; OCT / PRP / efficacy / readymade growth factors / skin rejuvenation
  •  go-up   go-down


34. Shinohara N, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S, Japanese Society of Renal Cancer: A randomized multicenter phase II trial on efficacy of high-slip skin care pad for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. J Clin Oncol; 2011 May 20;29(15_suppl):TPS233
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized multicenter phase II trial on efficacy of high-slip skin care pad for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
  • : TPS233 Background: Hand-foot skin reaction (HFSR) is the most clinically significant dermatologic toxicity in patients (pts) with metastatic renal cell carcinoma (mRCC) who receive sorafenib.
  • HFSR may be attributed to keratinous disorders of the skin and tends to develop in particular in areas on the soles of the feet subject for strong pressure.
  • Since high-slip skin care pad (Remois pad) is a protective dressing on pressure ulcer to reduce surface pressure and to result in the prevention of skin damage, the characteristics of this material may prevent the development and worsening of HFSR.
  • The purpose of the study is to investigate the usefulness of a high-slip skin care pad for HFSR on the soles.
  • Pts are randomized into two groups: high-slip skin care pad group versus 10% urea cream group.
  • High slip skin care pad is recommended to change every 2-3 days, and 10% urea cream is ordered to apply and rub to affected sites 2 or 3 times per day.
  • Secondary endpoints are treatment compliance (dose reduction/discontinuation of sorafenib), pain assessment (visual analogue scale), and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28023523.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Zapletalova A, Pata V, Janis R, Kejlova K, Stoklasek P: Objective measurements of skin surface roughness after microdermabrasion treatment. Skin Res Technol; 2017 Jan 12;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective measurements of skin surface roughness after microdermabrasion treatment.
  • BACKGROUND: The aim of this article is to present a new methodology for assessment of skin topology using a three-dimensional image (3D).
  • METHODS: The measurement of the skin surface roughness is based on 3D scanning of silicone replicas by chromatic aberration length technique in a contactless manner, i.e. by a polychromatic light beam.
  • Analysis of the skin surface reprints was performed using Talymap, Gold version.
  • Results were analysed by fractal geometry, which allows to evaluate changes of the skin surface before and after application of cosmetics and instrumental cosmetological techniques.
  • The methodology was applied for objective assessment of the effects of diamond microdermabrasion on the skin surface roughness.
  • RESULTS: Based on the results of skin surface scanning after the treatment with diamond microdermabrasion it may be concluded that inequalities of the skin surface are reduced immediately after exfoliation.
  • The entire study ultimately suggests that the instrumental method used only leads to improvement of the skin surface immediately after its application.
  • Thermo vision images of the skin surface temperature were obtained during the application of the abrasive method.
  • The experimental results showed that the skin is rather cooled than heated by the treatment.
  • CONCLUSION: This study is focused on the development of a methodology for objective measurement of changes in treated skin relief using 3D scanning.
  • The output may also include also an enlarged model of the skin surface made by 3D printer, which can serve for illustrative communication with the client.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28083897.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3D scanning / claim substantiation / microdermabrasion / replication / skin structure / statistics
  •  go-up   go-down


36. Lin J, Beer TM, Ryan CJ, Mathew P, Wilding G, Morris M, Callahan JA, Gordon G, Reich S, Carducci MA: A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):5135
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endpoints included the proportion of pts who did not have PSA progression for 24 weeks, change in PSA slope/PSADT, and assessment of safety and tolerability.
  • ATN-224 was well tolerated with a few reversible Grade 3/4 neutropenia and Grade 3 skin rash (both 4%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger HF, Oruzio DV, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf HW, Mittermueller J, Haberl C, Giessen CA, Moosmann N, Stintzing S: Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. J Clin Oncol; 2011 May 20;29(15_suppl):3589
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
  • : 3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC).
  • Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab.
  • The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy.
  • RESULTS: Of 185 recruited patients, 149 patients (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumor assessment and were evaluable for efficacy.
  • While cetuximab-specific skin toxicity such as acneiform rash, dry skin and others occurred in >90% of patients, Cape-ST, predominantly hand-foot syndrome, was observed in only 33.2% of patients.
  • CONCLUSIONS: This analysis supports the hypothesis that for the evaluated regimens a correlation exists between capecitabine-specific skin toxicity and treatment efficacy regarding DCR, PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Few J, Gold M, Sadick N: Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With Multipolar Radiofrequency andVaripulseTechnology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks. J Drugs Dermatol; 2016 Nov 01;15(11):1354-1358
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With Multipolar Radiofrequency andVaripulseTechnology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks.
  • BACKGROUND: Increasing demand for non-invasive skin tightening and body contouring procedures has led to several technological in- novations in energy-based devices such as ultrasound, radiofrequency and cryolipolysis.
  • An emerging trend in the eld is to evaluate whether combination therapies for skin laxity/body contouring using energy-based devices can deliver superior clinical results and patient satisfaction.
  • As such, the objective of this prospective, internal-controlled, blind clinical study was to assess the safety and efficacy of cryolipolysis followed by multipolar radiofrequency with pulsed electromagnetic elds (PEMF) and adjustable pulsed suction for the treatment of skin laxity in the flanks.
  • Side effects were recorded at every visit and patient satisfaction was noted at the one week, three and six-month follow-up using a 5-scale subject satisfaction assessment questionnaire.
  • RESULTS: Analysis of the blinded investigator ratings demonstrated statistical significant enhanced skin laxity mean improvement of 1 grade on the GAI scale in subject treated with the combination treatment (cryolipolysis+RF/PEMF/suction) compared with the cryolipolysis treatment alone.
  • CONCLUSION: The results of this study show that the combination of multipolar RF with PEMF/suction following cryolipolysis is a safe, effective, and painless approach to enhance skin tightening following fat reduction procedures in the flanks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095547.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Abruzzo A, Armenise N, Bigucci F, Cerchiara T, Gösser MB, Samorì C, Galletti P, Tagliavini E, Brown DM, Johnston HJ, Fernandes TF, Luppi B: Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone. Int J Pharm; 2017 Mar 27;524(1-2):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone.
  • One of the most widely used approaches for improving drug permeation across the stratum corneum barrier of the skin is the use of chemical penetration enhancers, such as surfactants.
  • Assessment of impacts on HaCaT keratinocyte cell viability was used as indicator of their potential to cause skin irritation 24h post exposure (Alamar Blue assay).
  • The effect of different surfactant concentrations (up to ten times the critical micellar concentration, CMC) on hydrocortisone (HC) solubility and permeation through porcine skin was also evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28356226.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Cytotoxicity / Hydrocortisone / Keratinocyte / Micellar solubilization / Skin permeation enhancement / Surfactants
  •  go-up   go-down


40. Narita K, Vo PTH, Yamamoto K, Kojima H, Itagaki H: Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays. Toxicol In Vitro; 2017 Apr 11;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays.
  • In vitro safety tests may be used as replacements for animal tests owing to their accuracy and high-throughput performance.
  • However, several in vitro skin sensitization tests produce false-negative results such as acid anhydride.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Ltd.
  • (PMID = 28411127.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative / Drug exposure / False-negative / In vitro / Skin sensitization test / THP-1 cells
  •  go-up   go-down


41. Sowada J, Lemoine L, Schön K, Hutzler C, Luch A, Tralau T: Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin. Arch Toxicol; 2017 Apr 04;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin.
  • This study now shows that readily isolable skin commensals transform B[a]P into a range of highly cyto- and genotoxic metabolites that are excreted in toxicologically relevant concentrations during growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28378121.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Benzo[a]pyrene / Cytotoxicity / Genotoxicity / Microbiome / PAHs / Polycyclic aromatic hydrocarbons / Toxification
  •  go-up   go-down


42. Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, Payne A, Koch A, Healy E: First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. Eur J Clin Pharmacol; 2017 May;73(5):581-591
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.
  • Pharmacodynamic effects on markers of inflammation were assessed via changes in ex vivo basophil degranulation and histological assessment of psoriatic skin biopsies.
  • No safety concerns or dose-limiting toxicities were identified (Study-1).
  • Pharmacodynamic findings demonstrated ex vivo inhibition of basophil degranulation, improvements in histological assessment of skin biopsies and other markers of psoriatic biology and preliminary evidence of target engagement in psoriatic skin tissue.
  • CONCLUSIONS: Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28160012.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Inflammatory / PI3Kδ / Pharmacodynamic / Pharmacokinetic / Phase I / Seletalisib
  •  go-up   go-down


43. Katare OP, Raza K, Wadhwa S, Kumar P, Thotakura N: Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab; 2017 Mar 05;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To estimate the amount of drug delivery to skin, the scientists have now established techniques for separation of skin layers for the determination of drug concentrations.
  • This forms the basis of pharmacokinetics of drug(s) in skin, i.e., dermatokinetics.
  • Assessment of bioavailability helps in determination of safety and efficacy of topical formulations.
  • As the methods used for determination of pharmacokinetics of oral and intravenous formulations are not useful for dermatokinetic assessment, various methods like tape stripping, microdialysis and vasoconstrictor assays are being used for dermatokinetic assessment.These methods are not only useful to determine the drug concentrations in various skin layers, but can also be used to correlate the toxicity effects of xenobiotics with skin layer concentrations.
  • Despite advantages, there are some challenges in methodologies used for calculation of dermatokinetic parameters for furrows on skin and follicular drug penetration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
  • (PMID = 28266274.001).
  • [ISSN] 1875-5453
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Pharmacokinetics / confocal microscopy / follicular drug penetration / micro dialysis / tape stripping / trypsin digestion / vasoconstrictor assay
  •  go-up   go-down


44. Zhang W, Chen L, Chen J, Wang L, Gui X, Ran J, Xu G, Zhao H, Zeng M, Ji J, Qian L, Zhou J, Ouyang H, Zou X: Silk Fibroin Biomaterial Shows Safe and Effective Wound Healing in Animal Models and a Randomized Controlled Clinical Trial. Adv Healthc Mater; 2017 Mar 24;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here a silk fibroin film is developed and its translational potential is investigated for skin repair by performing comprehensive preclinical and clinical studies to fully evaluate its safety and effectiveness.
  • In vivo rabbit full-thickness skin defect study shows that the silk fibroin film effectively reduces the average wound healing time with better skin regeneration compared with the commercial wound dressings.
  • Subsequent assessment in porcine model confirms its long-term safety and effectiveness for full-thickness skin defects.
  • Therefore, the study provides systematic preclinical and clinical evidence that the silk fibroin film promotes wound healing thereby establishing a foundation towards its application for skin repair and regeneration in the clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28337854.001).
  • [ISSN] 2192-2659
  • [Journal-full-title] Advanced healthcare materials
  • [ISO-abbreviation] Adv Healthc Mater
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; bench to bedside / controlled clinical trial / silk fibroin biomaterial / skin repair and regeneration / wound healing
  •  go-up   go-down


45. Thomas KS, Bradshaw LE, Sach TH, Cowdell F, Batchelor JM, Lawton S, Harrison EF, Haines RH, Ahmed A, Dean T, Burrows NP, Pollock I, Buckley HK, Williams HC, Llewellyn J, Crang C, Grundy JD, Guiness J, Gribbin A, Wake EV, Mitchell EJ, Brown SJ, Montgomery AA: Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technol Assess; 2017 Apr;21(16):1-260
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families.
  • Secondary outcomes - patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility - 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness.
  • Safety outcomes - number of skin infections and hospitalisations for AE.
  • Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for standard care and silk clothing groups, respectively.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28409557.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Gold LS, Baldwin H, Rueda MJ, Kerrouche N, DrÉno B: Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged Females. J Clin Aesthet Dermatol; 2016 Jul;9(7):23-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Objectives:</b> To evaluate the efficacy and safety of adapalene 0.1% benzoyl peroxide 2.5% gel in women aged 25 years or older via subgroup analysis of existing Phase 2 and 3 study data.
  • Efficacy assessments included investigator's global assessment and median percent change in acne lesions.
  • Safety assessments included skin tolerability and adverse events.
  • Comparison of the amount of difference between active and vehicle reductions in investigator's global assessment showed that efficacy was similar for adult females versus teen-aged females (20.7% vs. 19.9%, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Exp Med Biol. 1999;455:477-82 [10599385.001]
  • [Cites] Am J Clin Dermatol. 2006;7(5):281-90 [17007539.001]
  • [Cites] Cutis. 2007 Aug;80(2):152-7 [17944177.001]
  • [Cites] Cutis. 2009 Aug;84(2):110-6 [19746769.001]
  • [Cites] Dermatol Res Pract. 2010;2010:null [20706683.001]
  • [Cites] J Clin Aesthet Dermatol. 2015 Jan;8(1):31-7 [25610522.001]
  • [Cites] Skinmed. 2014 Jan-Feb;12(1):15-21 [24720080.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5):791-9 [17655969.001]
  • [Cites] Cutis. 2014 Oct;94(4):177-82 [25372252.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1063-70 [23302006.001]
  • [Cites] J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50 [19376456.001]
  • [Cites] Mini Rev Med Chem. 2014;14(8):629-41 [25141855.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1096-106 [25296739.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37 [12833004.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2012 Mar;26(3):277-82 [21848892.001]
  • [Cites] Cutis. 2003 Feb;71(2 Suppl):18-26 [12630671.001]
  • [Cites] Br J Dermatol. 2009 Nov;161(5):1180-9 [19466959.001]
  • [Cites] J Am Acad Dermatol. 1999 Oct;41(4):577-80 [10495379.001]
  • [Cites] J Clin Aesthet Dermatol. 2014 Feb;7(2):22-30 [24578779.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 May;23 (5):529-32 [19192015.001]
  • [Cites] J Clin Aesthet Dermatol. 2013 Oct;6(10):32-5 [24155991.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):644-6 [16546586.001]
  • [Cites] Clin Interv Aging. 2006;1(4):327-48 [18046911.001]
  • [Cites] Int J Dermatol. 2014 Jan;53(1):114-22 [24168514.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Apr;29(4):789-96 [25399481.001]
  • (PMID = 28331557.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Sasaki GH, Abelev N, Papadopoulos L: A Split Face Study to Determine the Significance of Adding Increased Energy and Treatment Levels at the Marionette Folds. Aesthet Surg J; 2017 Apr 07;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Background: Microfocused ultrasound with visualization (MFU-V) has become a safe and effective means to tighten skin and subdermal structures by optimizing the amount of joule energy and treatment tissue planes for improved customization for the individual patient.
  • Objectives: The aims of this institutional review board-approved investigation and clinical experience were to clarify the safety and efficacy of current treatment guidelines.
  • Clinical studies, utilizing these algorithms to treat regional areas of the forehead, periorbitum, face, neck, and décolleté, were analyzed by (IGIAS) assessment, pain scoring, and incidence of complications and side effects at D180 and D360.
  • Results: Post hoc analyses at D180 and D360 in pilot studies 1 and 2 demonstrated greater tissue displacements, elasticity measurement, and pain scores, supported by SGAIS and IGAIS assessment with the use of higher amounts of joule energy and treatment planes than those used on the contralateral reference marionette folds at D180 and D360.
  • Conclusions: Optimization, customization, and safety were observed with the use of current MFU-V algorithms as clarified by the findings in this investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28398471.001).
  • [ISSN] 1527-330X
  • [Journal-full-title] Aesthetic surgery journal
  • [ISO-abbreviation] Aesthet Surg J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Lacour JP, Paul C, Jazayeri S, Papanastasiou P, Xu C, Nyirady J, Fox T, Papavassilis C: Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol; 2017 Jan 23;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection.
  • Efficacy responses [≥75/90/100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100) and clear/almost clear skin by Investigator's Global Assessment 2011 modified version (IGA mod 2011 0/1)] were measured at Week 52.
  • Patient-reported usability of the autoinjector was evaluated by the self-injection assessment questionnaire to Week 48.
  • CONCLUSION: Self-administration of secukinumab using an autoinjector was associated with robust and sustained efficacy, a good safety profile and high acceptability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28111801.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Raoul J, Craxi A, Porta C, Lentini G, Nadel A, Voliotis D, Bruix J, Llovet JM: Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15547
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15547 Background: Results from the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, a multinational, randomized, placebo-controlled, phase III trial, demonstrated that sorafenib is effective and safe for patients with advanced HCC (Llovet et al, N Engl J Med, 2008).
  • As lymph nodes are among the most common sites of metastasis in patients with HCC, we performed subset analyses to evaluate the efficacy and safety of sorafenib in patients with or without lymph node metastases at baseline.
  • End points included overall survival (OS), disease-control rate (DCR; defined as complete/partial response or stable disease by RECIST, maintained for ≥28 d from first demonstration of response), time to progression (TTP), and safety.
  • The most common grade 3/4 adverse events in the sorafenib populations were hand-foot skin reaction and diarrhea.
  • The safety profile of sorafenib in patients with lymph node metastases was comparable with that for the overall study population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Abdel-Meguid AM, Taha EA, Ismail SA: Combined Jessner Solution and Trichloroacetic Acid Versus Trichloroacetic Acid Alone in the Treatment of Melasma in Dark-Skinned Patients. Dermatol Surg; 2017 Feb 06;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Melasma is a common challenging pigmentary skin disorder especially in dark-skinned females urging them to seek medical help.
  • OBJECTIVE: To compare safety and efficacy of combined trichloroacetic acid (TCA) (20%-25%) and Jessner's solution versus TCA (20%-25%) alone in dark patients with melasma.
  • Twenty-four adult female patients (skin phototypes IV-V) with bilateral melasma were treated for 6 sessions at 2 weeks intervals.
  • Clinical assessment of the 2 sides of the face with Melasma Area and Severity Index (MASI) score was performed, and photographs were taken before and after the peeling course.
  • CONCLUSION: Dark skin melasma can be treated with both regimens safely and effectively; however, combined Jessner solution and TCA is more effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28178004.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Cheng CY, Huang YL, Lee MC, Chang SL, Lin YF, Hu S: Pulsed Alexandrite laser for treatment of melasma in Asian patients. J Cosmet Laser Ther; 2017 Feb 02;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was conducted to evaluate the efficacy and safety of pulsed Alexandrite laser for the treatment of melasma.
  • The severity of melasma was evaluated by a blinded dermatologist, using the Modified Melasma Area and Severity Index (MMASI), and by patient assessment, using a visual analogue scale, at baseline, before each treatment, and at the 1-month and 3-month follow-up visits after the last treatment.
  • The treatments were well tolerated with only mild skin reaction.
  • Conclusion In the present study, we demonstrated that the pulsed alexandrite laser is safe and effective to treat melasma in Asian skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151024.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alexandrite laser / Asian / melasma
  •  go-up   go-down


52. Wang S, Mi J, Li Q, Jin R, Dong J: Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients. Lasers Surg Med; 2017 Feb 20;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the various techniques, fractional microplasma radiofrequency technology (FMRT) has proven to be an effective treatment option for various types of scars and skin conditions such as rhytids, striae distensae, and hyperpigmentation.
  • OBJECTIVE: This prospective clinical trial was designed to evaluate the efficacy and safety of FMRT for treating non-hypertrophic post-burn scars in the Asian population.
  • The Patient and Observer Scar Assessment Scales (POSAS) [20] were used to evaluate changes in burn scars pre-and post-FMRT treatment.
  • No severe adverse events, such as acute skin infection, hypertrophic scarring, or depigmentation, were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28220505.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; burns / cicatrix / lasers / micro-plasma / radiofrequency / scars
  •  go-up   go-down


53. Greveling K, Prens EP, Liu L, van Doorn MB: Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review. J Eur Acad Dermatol Venereol; 2017 Jan 20;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive anaesthetic methods during dermatological laser procedures.
  • The quality of evidence was rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
  • The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin cooling, and pneumatic skin flattening [PSF]), types of lasers, laser settings, application time, and types of pain scales varied widely among the included studies.
  • In general, active non-invasive anaesthetic methods seemed to provide favourable results compared to placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed to result in a better pain reduction than skin cooling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107576.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


54. Svedlund E, Larsson M, Hägerkvist R: Spontaneously Reported Adverse Reactions for Herbal Medicinal Products and Natural Remedies in Sweden 2007-15: Report from the Medical Products Agency. Drugs Real World Outcomes; 2017 Mar 28;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In relation to the extensive use of herbal medicinal products in self-care, the safety information is limited and there is a need for improvement.
  • Adverse reactions related to skin and subcutaneous tissue were the most commonly reported reactions.
  • CONCLUSIONS: No previously unknown safety problems have been discovered in the present study.
  • This finding could be explained by a thorough pre-approval assessment of medicinal products and the fact that most herbal preparations in medicinal products have been in clinical use for many years (for traditional herbal medicinal products, the requirements are ≥30 years), i.e. adverse reactions are acknowledged and assessed before approval.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28353157.001).
  • [ISSN] 2199-1154
  • [Journal-full-title] Drugs - real world outcomes
  • [ISO-abbreviation] Drugs Real World Outcomes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


55. Jacques-Jamin C, Jeanjean-Miquel C, Domergue A, Bessou-Touya S, Duplan H: Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis. Skin Pharmacol Physiol; 2017 Mar 10;30(2):55-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis.
  • BACKGROUND: Information is lacking on the dermal penetration of topically applied formulations on in vitro skin models, under conditions where the stratum corneum (SC) is damaged.
  • Therefore, we have developed a standardized in vitro barrier-disrupted skin model using tape stripping.
  • RESULTS: The effects of tape stripping were comparable using pig and human skin.
  • The bioavailability of the filters was extremely low regardless of the extent of skin damage, suggesting bioavailability would not be increased if the consumer applied the sunscreen to sun-damaged skin.
  • CONCLUSION: This standardized in vitro methodology using pig or human skin for damaged skin will add valuable information for the safety assessment of topically applied products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28278501.001).
  • [ISSN] 1660-5535
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


56. Naqi N, Ahmad S, Murad S, Khattak J: A phase II feasibility study of sorafenib and gemcitabine combination therapy in advanced hepatocellular carcinoma. J Clin Oncol; 2011 Feb;29(4_suppl):298
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to evaluate the efficacy and safety of sorafenib and gemcitabine combination in advanced HCC.
  • National Cancer Institute criteria for adverse events (NCI CTCAE) Version 3.0, and Response evaluation criteria for solid tumors (RECIST) was used for assessment.
  • 8 patients had progressive disease, 4 progressing on interim assessment were taken off protocol.
  • Sorafenib specific, hand foot skin reaction and anorexia were next most frequent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung JW, Siedentop H, Molnar I, Schlumberger M: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol; 2013 Jun 20;31(18_suppl):4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The double-blind, randomized, multicenter phase III DECISION trial examined sorafenib efficacy and safety vs placebo in patients with progressive RAI-refractory DTC.
  • Secondary endpoints included overall survival (OS), response rate (RR; complete + partial response [PR]), and safety.
  • Tumor histology by independent assessment was 57% papillary, 25% follicular, and 10% poorly differentiated.
  • The most common any-grade treatment-emergent adverse events in the sorafenib arm included hand-foot skin reaction, diarrhea, alopecia, rash/desquamation, fatigue, weight loss and hypertension.
  • Tolerability was consistent with the known sorafenib safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28136058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ, UK Dermatology Clinical Trials Network BLISTER Study Group: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet; 2017 Mar 06;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality.
  • We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.
  • The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks.
  • Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed.
  • FUNDING: NIHR Health Technology Assessment Programme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
  • (PMID = 28279484.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Adams J; Akhras V; Anstey A; Barnard C; Bell H; Blackford S; Bröcker E; Carmichael A; Coelho RR; Craig F; Davies K; Ellis R; English J; Gläser R; Groves R; Günthert C; Hampton PJ; Hepburn N; Hügel R; Hussain K; Ingram J; Layton AM; Levell NJ; Lewis V; Malhomme H; Omerod A; Patel G; Rallan R; Ravenscroft J; Santander H; Steinbrink K; Sticherling M; Thomas C; Vatve M; van Beek N; Venning V; Veysey E; Wachsmuth R; Wahie S; Walker B; Walsh M; Wee J; Westmoreland M; Wong G; Ferguson A; Verpetinske I; Duarte-Williamson E; Antony F; Bower C; Gawkrodger D; Taghipour K; Dunnill MG; Waters A; Bottomley W; Wright A; Sterling J; Azam A; Gibbs S; Luger T; Salvary I; Lovell C; Ilchyshyn A; Gibbon K; Nik M; Charles-Holmes R; Lavery AL
  •  go-up   go-down


59. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7083
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a report of results from part 1 of a 2-part, phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics (PK) of ABX-EGF in combination with paclitaxel and carboplatin for advanced NSCLC.
  • One pt (5%) had a confirmed complete response (1.0 mg/kg) and 4 pts (21%) had partial responses (2 at 2.0 mg/kg and 2 at 2.5 mg/kg) by investigator assessment.
  • The most common adverse event (AE) was skin rash (89% overall; 83%, 100%, and 83% in the 1.0, 2.0, and 2.5 mg/kg groups).
  • The incidence of grade 3 skin rash did not appear to increase with dose (17% at 1.0 mg/kg, 29% at 2.0 mg/kg, and 0% at 2.5 mg/kg).
  • Four pts (1 at 1.0 mg/kg and 3 at 2.0 mg/kg) had ABX-EGF dosing interrupted or reduced because of skin toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Guo Y, Gu Z, Liu X, Liu J, Ma M, Chen B, Wang L: Rapid Analysis of Corni fructus Using Paper Spray-Mass Spectrometry. Phytochem Anal; 2017 Feb 26;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a number of counterfeits of Corni fructus, such as Crataegi fructus, Lycii fructus, and grape skin are illegally sold in crude herb markets.
  • Therefore, the development of a rapid and high-throughput quality evaluation method is important for ensuring the effectiveness and safety of the crude materials of Corni fructus.
  • OBJECTIVE: To develop PS-MS chemical profiles and a semi-quantitative method of Corni fructus for quality assessment and control, and species distinction of Corni fructus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 John Wiley & Sons, Ltd.
  • (PMID = 28239915.001).
  • [ISSN] 1099-1565
  • [Journal-full-title] Phytochemical analysis : PCA
  • [ISO-abbreviation] Phytochem Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Corni fructus / chemical profile / paper spray-mass spectrometry / rapid analysis / species distinction
  •  go-up   go-down


61. Stintzing S, Neumann J, Jung A, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jaeger E, Heintges T, Stoll C, Modest DP, Kirchner T, Scheithauer W, Heinemann V: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. J Clin Oncol; 2011 May 20;29(15_suppl):3575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3575 Background: The German AIO study KRK-0306 is a randomized phase III trial that investigates the efficacy and safety of cetuximab plus FOLFIRI versus bevacizumab plus FOLFIRI in the first-line treatment of mCRC.
  • Secondary endpoints were progression-free survival (PFS), overall survival (OS), rate of secondary liver resections, toxicity and safety.
  • In pts assessable for treatment efficacy (on treatment until the first tumor assessment) receiving arm A (n=41) versus arm B (n=46), ORR was 43.9% versus 47.8%.
  • In arm A skin rash grade 1-4 was associated with a trend towards longer PFS (7.6 versus 3.5 months, logrank p=0.108).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020264.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Trarbach T, Beyer T, Schleucher N, Stattaus J, Mueller SP, Appel D, Tillner J, Schmid KW, Seeber S, Vanhoefer U: A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):3018
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A phase I study was conducted to assess the safety and anti-tumor activity of EMD 72000 in 24 patients with advanced refractory gastrointestinal tumors.
  • Skin and tumor biopsies were obtained before treatment and at wks 4 (skin only) and 8.
  • No NCI-CTC grade 3 or 4 drug-related toxicities were observed; grade 1/2 skin reaction was seen in > 80% of subjects with doses ≥ 200 mg.
  • Assessment of metabolic response by PET-CT using EORTC criteria in 18 patients after 4 wks on study showed 1 CR (800 mg), 6 PR (2 each at 400 and 800 mg, 1 each at 100 and 200 mg), and 9 SD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015164.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chi Y, Zheng Z, Zhou A, Yang L, Qu T, Jiang W, Shi S, Sun Y, Song Y, Kang S, Wang J: Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e21021
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21021 Background: Nimotuzumab, a humanized IgG1 anti-EGFR monoclonal antibody, has demonstrated efficacy associated with an absence of severe skin toxicity in many phase I/II cancer trials.
  • The primary endpoint was ORR and the secondary endpoints included TTP, PFS, 1-year survival rates and safety.
  • Up to 2011-01-14, 36 patients (NCS 19 cases compared with CS 17) have undergone efficacy assessment.
  • No adverse events of grade 3 skin rash or grade 3 infusion-related reactions were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Robert F, Verschraegen C, Hurwitz H, Uronis H, Advani R, Chen A, Taverna P, Wollman M, Fox J, Michelson G: A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):2536
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoints: safety, tolerability, and DLT assessment.
  • Pharmacodynamic endpoint was inhibition of Histone H3 phosphorylation (pHH3) evaluated by immunohistochemistry of skin punch biopsies taken pre- and 2 hours post-infusion.
  • Inhibition of pHH3 by SNS-314 was observed in skin biopsies of patients treated at doses of 240 mg/m<sup>2</sup> and greater.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Dall'oglio F, Tedeschi A, Fusto CM, Lacarrubba F, Dinotta F, Micali G: A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: a open-label trial utilizing clinical evaluation and erythemadirected digital photography. G Ital Dermatol Venereol; 2017 Jan 24;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced digital photography, equipped with technology able to provide a detailed evaluation of red skin components corresponding to vascular flare (erythema-directed digital photography), is a useful tool for evaluation of erythema in patients affected by inflammatory dermatoses.
  • The aim of this study was to assess the efficacy and safety of a new cosmetic topical gel containing ciclopiroxolamine, lactoferrin, glycero-phosphoinositol (GPI) and Aloe vera, for the treatment of facial seborrheic dermatitis by clinical and advanced digital photography evaluation.
  • Finally, at baseline and at the end of the study IGA (Investigator Global Assessment) was performed using a 5-point severity scale (from 0 =worsening to 4= excellent response).

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121079.001).
  • [ISSN] 1827-1820
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Rubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol; 2011 May 20;29(15_suppl):3004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib.
  • In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD.
  • Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol; 2004 Jul 15;22(14_suppl):4501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typical drug-related toxicities were hand-foot skin reaction, rash, fatigue, diarrhea, anorexia and hypertension.
  • Of the 112 pts with RCC, 65 pts have reached the initial 12-week assessment (63 evaluable for response).
  • The randomized portion will provide information about BAY's disease-stabilizing effect and long-term safety, in particular in pts with RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P: Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med; 2016 Dec 19;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : ECa 233, a standardized extract of <i>Centella asiatica</i>, has been found to exhibit various positive neurological effects and to have a good safety profile.
  • The results showed that all animals had a good tolerability for ECa 233, whereas madecassic and asiatic acids were found in negligible amounts after pharmacokinetic assessment.
  • Both triterpenoids were extensively distributed in the brain, stomach, and skin within 1 h and remained there for at least 4 h after dosing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 27992940.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Guarneri A, Cioni M, Rongioletti F: High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol; 2017 Mar 29;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of high-dose intravenous immunoglobulin (IVIg) for the management of scleromyxoedema prospectively using an objective score.
  • The patients were followed-up to a minimum of 6 months, and their disease activity and response to treatment were assessed using the Physician's Global Assessment of disease severity (PGA) and a modified objective skin scoring system for patients with scleroderma (modified Rodnan score system for scleromyxoedema or mRSSS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28370513.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Duvic M, Ziari S, Olsen EA, Foss FM: Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6733
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells.
  • Clinical response was determined each course using a weighted composite of disease assessment from baseline.
  • Safety visits were conducted weekly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3511
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This phase 2 study assessed the efficacy and safety of ABX-EGF monotherapy in pts with mCRC who previously failed therapy with a fluoropyrimidine and irinotecan or oxaliplatin or both.
  • Of 148 pts with evaluations after 8 weeks, 15 (10.1%; 95%CI: 5.8%, 16.2%) had confirmed partial responses (12 cohort A, 3 cohort B) and 54 (36.5%) had stable disease (39 cohort A, 15 cohort B) by investigator assessment.
  • The most frequent adverse event (AE) was skin rash (> 90%) [3.4% grade 3].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Roberts DW, Aptula A, Api AM: Structure-Potency Relationships for Epoxides in Allergic Contact Dermatitis. Chem Res Toxicol; 2017 Feb 20;30(2):524-531
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Epoxides are known or proposed to be involved in skin sensitization in various ways.
  • To date no quantitative mechanistic models (QMMs) are known for skin sensitization potency of this subcategory of S<sub>N</sub>2 electrophiles.
  • The epoxide QMM predicts the potency of a nonepoxide S<sub>N</sub>2 electrophile (predicted EC3, 0.48%; observed EC3, 0.5%), which suggests that it could form the basis for a more general H-polar S<sub>N</sub>2 QMM that could be a valuable tool in skin sensitization risk assessment for this quite extensive and structurally diverse reaction mechanistic domain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121139.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Cohn AL, Smith DA, Neubauer MA, Houston G, Khandelwal P, Wiggans RG, Zhang K, Yassine M: Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. J Clin Oncol; 2009 May 20;27(15_suppl):4067
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy (objective response, progression-free survival [PFS], and overall survival [OS]) and safety were evaluated by KRAS status.
  • RESULTS: In an interim analysis (May 2008) of 115 pts who had received ≥ 1 dose of pmab, 109 pts had known KRAS status (59% had tumors with wild-type [WT] KRAS, 41% had mutant [MT] KRAS tumors), and 102 pts had the opportunity to have their first tumor assessment.
  • Most common AEs were skin-related toxicities (86% of pts), diarrhea (72%), and nausea (53%); there was no evidence that incidence of AEs was related to KRAS status.
  • Pmab had a safety profile consistent with other FOLFIRI + pmab trials.
  • Final efficacy and safety data will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Jones K, Johnson PD, Baldwin PE, Coldwell M, Cooke J, Keen C, Harding AH, Smith D, Cocker J: Exposure to Diisocyanates and Their Corresponding Diamines in Seven Different Workplaces. Ann Work Expo Health; 2017 Feb 14;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of this, any exposure to the diamines themselves released during the industrial process could confound the assessment of diisocyanate exposure.
  • This paper reports an initial assessment of the extent of diamine formation and exposure during different processes involving diisocyanates including casting, grouting, core making, spray painting, foam blowing, and floor screeding.
  • Some non-aerosol processes gave rise to substantial diamine levels in urine (in exceedance of international guidance values, >5 µmol mol-1 creatinine) despite airborne levels being well within occupational exposure limits (20 µg m-3 total NCO in Great Britain); measurement data and statistical modelling indicated that skin absorption was the most likely exposure route.
  • It also demonstrates the potential for substantial skin absorption of diisocyanates in certain processes such as floor screeding and foam production.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Crown copyright 2017.
  • (PMID = 28355438.001).
  • [ISSN] 2398-7316
  • [Journal-full-title] Annals of work exposures and health
  • [ISO-abbreviation] Ann Work Expo Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; NCO / diamines / diisocyanates / floor screeding / foam blowing / skin absorption
  •  go-up   go-down


75. Vukmanović S, Sadrieh N: Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening. Crit Rev Toxicol; 2017 Mar 22;:1-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening.
  • The combination of the proposed tests, along with the existing assays, should further enhance animal-free assessment of sensitizing potential of individual chemicals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326907.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Allergic contact dermatitis / HLA / T cells / cosmetics / delayed-type hypersensitivity / dendritic cells / fragrance / hapten / human-repeated insult patch test / keratinocytes / local lymph node assay / skin sensitization
  •  go-up   go-down


76. Luton A, Hernandez J, Patterson CR, Nielsen-Farrell J, Thompson A, Kaiser JR: Preventing Pressure Injuries in Neonates Undergoing Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: An Interprofessional Quality Improvement Project. Adv Neonatal Care; 2017 Jan 30;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interventions centered on revision of current protocols, with efforts to optimize product selection, hardwire assessment practices, and refine documentation of patient care and outcomes.
  • IMPLICATIONS FOR PRACTICE: Recognizing the unique skin protection needs of special populations within the NICU, such as those undergoing TH, is crucial.
  • IMPLICATIONS FOR RESEARCH: A paucity of literature regarding the unique skin protection needs for babies undergoing TH exists.
  • Work should be done to better describe the influence of TH on skin integrity, with the goal of identifying population-specific protective measures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28141600.001).
  • [ISSN] 1536-0911
  • [Journal-full-title] Advances in neonatal care : official journal of the National Association of Neonatal Nurses
  • [ISO-abbreviation] Adv Neonatal Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, Klambauer G, Landesmann B, Luijten M, MacKay C, Maxwell G, Meek ME, Paini A, Perkins E, Sobanski T, Villeneuve D, Waters KM, Whelan M: How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology. Toxicol Sci; 2017 Feb;155(2):326-336
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts are underway to transform regulatory toxicology and chemical safety assessment from a largely empirical science based on direct observation of apical toxicity outcomes in whole organism toxicity tests to a predictive one in which outcomes and risk are inferred from accumulated mechanistic understanding.
  • We argue that the systematic organization of knowledge into AOP frameworks can inform and help direct the design and development of computational prediction models that can further enhance the utility of mechanistic and in silico data for chemical safety assessment.
  • Examples of AOP-informed model development and its application to the assessment of chemicals for skin sensitization and multiple modes of endocrine disruption are provided.
  • The role of problem formulation, not only as a critical phase of risk assessment, but also as guide for both AOP and complementary model development is described.
  • The contents serve as a vision for how AOPs can be leveraged to facilitate development of computational prediction models needed to support the next generation of chemical safety assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology.
  • [Cites] Toxicol Sci. 2013 Mar;132(1):75-86 [23288054.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1333-47 [25824844.001]
  • [Cites] Environ Toxicol Chem. 2015 Jul;34(7):1623-33 [25943079.001]
  • [Cites] Toxicology. 2012 Jan 27;291(1-3):18-24 [22120538.001]
  • [Cites] Environ Toxicol Chem. 2010 Mar;29(3):730-41 [20821501.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1875-87 [26360911.001]
  • [Cites] PLoS One. 2013 May 30;8(5):e63308 [23737943.001]
  • [Cites] Environ Health Perspect. 2016 May;124(5):556-62 [26431337.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):51-138 [20574894.001]
  • [Cites] Bioinformatics. 2012 May 1;28(9):1193-201 [22423044.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Toxicol Sci. 2015 Feb;143(2):319-32 [25338925.001]
  • [Cites] Environ Health Perspect. 2013 Sep;121(9):1002-10 [23771518.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2016 May-Jun;183-184:36-45 [26875912.001]
  • [Cites] Regul Toxicol Pharmacol. 2010 Dec;58(3):369-81 [20801182.001]
  • [Cites] Ann N Y Acad Sci. 2007 Dec;1115:1-22 [17925349.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Toxicol Sci. 2013 Jun;133(2):234-47 [23475784.001]
  • [Cites] Environ Res. 2012 Aug;117:90-9 [22770859.001]
  • [Cites] Environ Toxicol Chem. 2011 Feb;30(2):265-73 [21072840.001]
  • [Cites] BMC Syst Biol. 2011 May 05;5:63 [21545743.001]
  • [Cites] Int J Androl. 2008 Apr;31(2):209-23 [18217984.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):230-40 [19010444.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):14-25 [26500288.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Toxicol In Vitro. 2014 Feb;28(1):8-12 [24184331.001]
  • [Cites] Environ Sci Technol. 2016 May 3;50(9):4579-86 [26759916.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):471-83 [25236459.001]
  • [Cites] Environ Sci Technol. 2015 Jul 21;49(14):8804-14 [26066997.001]
  • [Cites] Toxicol In Vitro. 2015 Feb;29(1):259-70 [25448812.001]
  • [Cites] Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29 [23535119.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):259-71 [25440524.001]
  • [Cites] Nat Biotechnol. 2011 Sep 08;29(9):811-5 [21904331.001]
  • [Cites] Front Pharmacol. 2015 May 27;6:107 [26074819.001]
  • [Cites] Ecotoxicol Environ Saf. 2004 Sep;59(1):1-9 [15261716.001]
  • [Cites] Toxicol Sci. 2011 Dec;124(2):432-45 [21964421.001]
  • [Cites] Toxicol Sci. 2011 Feb;119(2):308-18 [20966114.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Aug;72(3):514-37 [25863193.001]
  • [Cites] Toxicol Sci. 2014 Dec;142(2):312-20 [25466378.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Apr;71(3):463-77 [25707856.001]
  • [Cites] Environ Health Perspect. 2014 Dec;122(12):1261-70 [25117432.001]
  • [Cites] Environ Res. 2012 Jul;116:74-84 [22575326.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Nat Biotechnol. 2015 Sep;33(9):933-40 [26258538.001]
  • [Cites] Chem Res Toxicol. 2012 Jul 16;25(7):1287-302 [22519603.001]
  • [Cites] Toxicology. 2015 Jun 5;332:112-23 [25598226.001]
  • [Cites] Environ Mol Mutagen. 2015 Jul;56(6):520-34 [25733247.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):137-54 [26272952.001]
  • [Cites] J Appl Toxicol. 2013 Nov;33(11):1353-64 [23670904.001]
  • [Cites] Altern Lab Anim. 2007 Mar;35(1):25-32 [17411348.001]
  • [Cites] PLoS One. 2016 Jan 12;11(1):e0146594 [26756814.001]
  • [Cites] ALTEX. 2013;30(4):473-86 [24173169.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1318-32 [25820183.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):453-61 [24994890.001]
  • (PMID = 27994170.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES016465
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; AOP / Adverse Outcome Pathways / computational prediction model. / quantitative AOP
  •  go-up   go-down


78. Politi Y, Levi A, Lapidoth M: Integrated Cooling-Vacuum-Assisted Non-Fractional 1540 nm Erbium:Glass Laser is Effective in Treating Acne Scars. J Drugs Dermatol; 2016 Nov 01;15(11):1359-1363
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mid-infrared laser skin interaction is characterized by its modest absorption in water and nite penetration to the mid-dermis.
  • OBJECTIVES: To evaluate the safety and efficacy of acne scars treatment using an integrated cooling-vacuum-assisted 1540 nm Erbium: Glass Laser.
  • Average improvement was 3.9 and 4.1 points on the quartile scale used for outcome assessment 1 and 3 months following the last session, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095548.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Friedman PM, Tolkachjov SN, Geddes ER, Tillman KA, Zachary CB: TRASER: An innovative device for the treatment of nasal telangiectasias. Lasers Surg Med; 2017 Apr 06;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
  • METHODS: Fifteen subjects aged 42-73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes.
  • Efficacy was measured by blinded analysis of pre and post images and self-assessment by the subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28382712.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TRASER / Total Reflection Amplification of Spontaneous Emission Radiation / pulse dye laser / pyrromethene / telangiectasias / total internal reflection / tunable wavelength / variable pulse duration
  •  go-up   go-down


80. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ: Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). J Clin Oncol; 2011 May 20;29(15_suppl):TPS124
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most drug-related adverse events were grade 1/2 in severity with the exception of grade 3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% in SOR+CAP vs 14% in PL+CAP).
  • Radiographic assessment is every 6 wk for the first 36 wk, and every 9 wk thereafter.
  • Secondary endpoints include overall survival, time to progression, overall response rate, duration of response (RECIST 1.1 criteria), and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Shen Y, Hsu C, Hsu C, Lin Z, Chen P, Shao Y, Huang T, Ding Y, Cheng A: A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4589
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase II study to evaluate the efficacy and safety of sorafenib plus low-dose UFT in advanced HCC patients (pts).
  • Tumor assessment was performed q8w by RECIST criteria.
  • Hand-foot skin reaction (HFSR), fatigue, and diarrhea were most common AEs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Lin WT, Chen WL, Cheng WC, Chang HC, Tsai SW: Determining the Residual Characteristics of Alkylphenols, Arsenic, and Lead as well as Assessing the Exposures of 1,4-Dioxane from Household Food Detergents. J AOAC Int; 2017 Feb 22;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the exposure assessment, it was estimated that the maximum amounts of 1,4-dioxane in contact with the skin from the use of household food detergent in Taiwan was 0.015 &#x03BC;g/kg/day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28330528.001).
  • [ISSN] 1060-3271
  • [Journal-full-title] Journal of AOAC International
  • [ISO-abbreviation] J AOAC Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Monastirli A, Pasmatzi E, Badavanis G, Tsambaos D: Gestational Pityriasis Rosea: Suggestions for Approaching Affected Pregnant Women. Acta Dermatovenerol Croat; 2016 Dec;24(4):312-313
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All miscarrying women reportedly revealed an aggressive course of widespread eruption and severe constitutional symptoms; all of them had HHV-6 DNA in the plasma, placenta, skin lesions, and fetal tissues, whereas HHV-7 DNA was detected in the plasma and skin lesions in 3 out of 8 (37.5%) miscarrying women.
  • HHV-6 DNA was found only in the plasma of 2 out of 31 women (6.45%) with normal pregnancy, whereas HHV-7 DNA was detected in the plasma of 3 (9.45%) and in the skin lesions of 2 women (6.45%) with normal pregnancy.
  • 4. Reliable and definite data from adequate and controlled human studies on the safety of acyclovir or valacyclovir in pregnant women and their efficacy in pityriasis rosea are lacking.
  • Thus, the decision on whether these antiviral compounds will be administered should be tailored to each individual pregnant woman, subsequent to a meticulous assessment of the potential risks and their balancing against the potential benefits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28128088.001).
  • [ISSN] 1847-6538
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


84. Ford KA: Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods. ILAR J; 2016 Dec;57(2):226-233
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Along with the potential capacity to reduce or replace the use of animals for the assessment of particular toxicological endpoints, computational models offer several advantages compared to in vitro and in vivo approaches, including cost-effectiveness, rapid availability of results, and the ability to fully standardize procedures.
  • Models are currently available to aid in the prediction of several important toxicological endpoints, including mutagenicity, carcinogenicity, eye irritation, hepatotoxicity, and skin sensitization, albeit with varying degrees of success.
  • This review serves to introduce the concepts of computational toxicology and evaluate their role in the safety assessment of compounds, while also highlighting the application of in silico methods in the support of the goal and vision of the 3Rs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Institute for Laboratory Animal Research.All rights reserved. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28053075.001).
  • [ISSN] 1930-6180
  • [Journal-full-title] ILAR journal
  • [ISO-abbreviation] ILAR J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3Rs / QSAR / alternative testing method / computational toxicology / drug development / in silico prediction
  •  go-up   go-down


85. Kendall R, Lenoir J, Gerrard S, Scheuerle RL, Slater NK, Tuleu C: Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System. Pharm Res; 2017 Feb 13;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.
  • However concerns exist around dermatological nipple tolerability with no pharmaceutical safety assessment guidance to study local tissue tolerance of the nipple and the areola.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28194635.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; nipple shield delivery system / pediatric / skin tolerability / slug mucosal irritation assay / tablet excipients
  •  go-up   go-down


86. Reisinger K, Hoffmann S, Alépée N, Ashikaga T, Barroso J, Elcombe C, Gellatly N, Galbiati V, Gibbs S, Groux H, Hibatallah J, Keller D, Kern P, Klaric M, Kolle S, Kuehnl J, Lambrechts N, Lindstedt M, Millet M, Martinozzi-Teissier S, Natsch A, Petersohn D, Pike I, Sakaguchi H, Schepky A, Tailhardat M, Templier M, van Vliet E, Maxwell G: Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. Toxicol In Vitro; 2015 Feb;29(1):259-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic evaluation of non-animal test methods for skin sensitisation safety assessment.
  • The need for non-animal data to assess skin sensitisation properties of substances, especially cosmetics ingredients, has spawned the development of many in vitro methods.
  • As it is widely believed that no single method can provide a solution, the Cosmetics Europe Skin Tolerance Task Force has defined a three-phase framework for the development of a non-animal testing strategy for skin sensitization potency prediction.
  • Ultimately, the testing strategy – combined with bioavailability and skin metabolism data and exposure consideration – is envisaged to allow establishment of a data integration approach for skin sensitisation safety assessment of cosmetic ingredients.
  • [MeSH-minor] Cell Line. Cosmetics. Epidermis / drug effects. Humans. In Vitro Techniques. Interleukin-18 / analysis. Keratinocytes / drug effects. Risk Assessment. Skin / drug effects. U937 Cells / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25448812.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Interleukin-18
  •  go-up   go-down


87. Macfarlane M, Jones P, Goebel C, Dufour E, Rowland J, Araki D, Costabel-Farkas M, Hewitt NJ, Hibatallah J, Kirst A, McNamee P, Schellauf F, Scheel J: A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: skin irritation. Regul Toxicol Pharmacol; 2009 Jul;54(2):188-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: skin irritation.
  • Evaluation of the skin irritancy and corrosivity potential of an ingredient is a necessity in the safety assessment of cosmetic ingredients.
  • To date, there are two formally validated alternatives to the rabbit Draize test for skin corrosivity in place, namely the rat skin transcutaneous electrical resistance (TER) assay and the Human Skin Model Test using EpiSkin, EpiDerm and SkinEthic reconstructed human epidermal equivalents.
  • For skin irritation, EpiSkin, EpiDerm and SkinEthic are validated as stand-alone test replacements for the rabbit Draize test.
  • In light of the deadlines established in the Cosmetics Directive for cessation of animal testing for cosmetic ingredients, a COLIPA scientific meeting was held in Brussels on 30th January, 2008 to review the use of alternative approaches and to set up a decision tree approach for their integration into tiered testing strategies for hazard and safety assessment of cosmetic ingredients and their use in products.
  • In conclusion, the safety assessments for skin irritation/corrosion of new chemicals for use in cosmetics can be confidently accomplished using exclusively alternative methods.
  • [MeSH-major] Animal Testing Alternatives / methods. Consumer Product Safety. Cosmetics / adverse effects. Skin / drug effects. Skin Irritancy Tests / methods

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19393278.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics
  •  go-up   go-down


88. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety assessment of triethanolamine and triethanolamine-containing ingredients as used in cosmetics. Int J Toxicol; 2013 May-Jun;32(3 Suppl):59S-83S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety assessment of triethanolamine and triethanolamine-containing ingredients as used in cosmetics.
  • The Cosmetic Ingredient Review Expert Panel assessed the safety of triethanolamine (TEA) and 31 related TEA-containing ingredients as used in cosmetics.
  • The TEA is reported to function as a surfactant or pH adjuster; the related TEA-containing ingredients included in this safety assessment are reported to function as surfactants and hair- or skin-conditioning agents.
  • Although data were not available for all the ingredients, the panel relied on the information available for TEA in conjunction with previous safety assessments of components of TEA-containing ingredients.
  • These data could be extrapolated to support the safety of all included ingredients.
  • [MeSH-major] Consumer Product Safety. Cosmetics / toxicity. Ethanolamines / toxicity

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • Hazardous Substances Data Bank. TRIETHANOLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23696578.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Ethanolamines; 9O3K93S3TK / triethanolamine
  • [Keywords] NOTNLM ; triethanolamine
  •  go-up   go-down


89. Johnson RS: Final report on the safety assessment of Cetethyl Morpholinium Ethosulfate. Int J Toxicol; 2001;20 Suppl 3:99-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final report on the safety assessment of Cetethyl Morpholinium Ethosulfate.
  • No other safety test data on this ingredient were available.
  • These data were clearly insufficient to support the safety of Cetethyl Morpholinium Ethosulfate in cosmetics.
  • Data available on Morpholine were summarized, but these data themselves were insufficient to support safety.
  • The data needed in order to complete the safety assessment of Cetethyl Morpholinium Ethosulfate include: methods of manufacture and impurities, especially nitrosamines; current concentration of use; skin penetration; if there is significant skin penetration, then both a 28-day dermal toxicity study to assess general skin and systemic toxicity and a reproductive and developmental toxicity study are needed; two genotoxicity studies, at least one in a mammalian system, if positive, then a 2-year dermal carcinogenisis study using National Toxicology Program (NTP) methods may be needed; ultraviolet (UV) absorption data, if significantly absorbed, then photosensitization data are needed; dermal irritation and sensitization; and ocular toxicity, if available.
  • [MeSH-minor] Animals. Eye Diseases / chemically induced. Humans. Inhalation Exposure / adverse effects. Nitrosamines / adverse effects. Nitrosamines / toxicity. Skin Diseases / chemically induced. Toxicity Tests, Acute. United States. United States Food and Drug Administration / standards

  • Hazardous Substances Data Bank. Morpholine .
  • Hazardous Substances Data Bank. N-NITROSOMORPHOLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11766137.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hair Preparations; 0 / Morpholines; 0 / Nitrosamines; 0 / Surface-Active Agents; 3L25FO7FN7 / N-nitrosomorpholine; 48SOX9D9O8 / cetethyl morpholinium; 8B2ZCK305O / morpholine
  • [Number-of-references] 8
  •  go-up   go-down


90. Andersen A: Amended final report of the safety assessment of dibutyl adipate as used in cosmetics. Int J Toxicol; 2006;25 Suppl 1:129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amended final report of the safety assessment of dibutyl adipate as used in cosmetics.
  • Dibutyl Adipate, the diester of butyl alcohol and adipic acid, functions as a plasticizer, skin-conditioning agent, and solvent in cosmetic formulations.
  • Clinical patch tests confirmed the absence of skin irritation found in animal tests.
  • The available data demonstrate no skin sensitization or cumulative skin irritation, no comedogenicity, and no genotoxicity.
  • Combined with the data demonstrating little acute toxicity, no skin or ocular irritation, and no reproductive or developmental toxicity, these data form an adequate basis for reaching a conclusion that Dibutyl Adipate is safe as a cosmetic ingredient in the practices of use and concentrations as reflected in this safety assessment.
  • [MeSH-minor] Animals. Dogs. Eye / drug effects. Female. Guinea Pigs. Humans. Male. Mice. Pregnancy. Rabbits. Rats. Rats, Sprague-Dawley. Reproduction / drug effects. Skin / drug effects

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835133.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipates; 0 / Cosmetics; F4K100DXP3 / dibutyl adipate
  •  go-up   go-down


91. Dincer Z, Jones S, Haworth R: Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse. Exp Toxicol Pathol; 2006 Jul;57(5-6):351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical safety assessment of a DNA vaccine using particle-mediated epidermal delivery in domestic pig, minipig and mouse.
  • An important aspect of the preclinical safety assessment of DNA vaccines is the selection of a pharmacologically relevant animal model for the assessment of antigen expression, optimization of delivery and formulation of the plasmid.
  • Pig/minipig is considered a good model for the safety assessment of DNA vaccines due to the similarity to human skin.
  • [MeSH-major] AIDS Vaccines / adverse effects. Biolistics. DNA, Viral / toxicity. Drug Evaluation, Preclinical. Skin / drug effects. Swine, Miniature. Vaccines, DNA / adverse effects

  • HIV InSite. treatment guidelines - HIV InSite .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713213.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / Adjuvants, Immunologic; 0 / DNA, Viral; 0 / HIV Antibodies; 0 / Vaccines, DNA; 7440-57-5 / Gold
  •  go-up   go-down


92. Fiume MM, Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Alkyl Esters as Used in Cosmetics. Int J Toxicol; 2015 Sep;34(2 Suppl):5S-69S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Alkyl Esters as Used in Cosmetics.
  • The Cosmetic Ingredient Review Expert Panel (Panel) assessed the safety of 237 alkyl esters for use in cosmetics.
  • The alkyl esters included in this assessment have a variety of reported functions in cosmetics, with skin-conditioning agent being the most common function.
  • The Panel reviewed available animal and clinical data in making its determination of safety on these ingredients, and where there were data gaps, similarity in structure, properties, functions, and uses of these ingredients allowed for extrapolation of the available toxicological data to assess the safety of the entire group.
  • [MeSH-major] Consumer Product Safety. Cosmetics / adverse effects. Cosmetics / chemistry. Esters / adverse effects
  • [MeSH-minor] Humans. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2015.
  • (PMID = 26362120.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Esters
  • [Keywords] NOTNLM ; alkyl esters / cosmetics / safety
  •  go-up   go-down


93. Hermanns JF, Piérard-Franchimont C, Piérard GE: Skin colour assessment in safety testing of cosmetics. An overview. Int J Cosmet Sci; 2000 Feb;22(1):67-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin colour assessment in safety testing of cosmetics. An overview.
  • Few subjects are as problematical to dermatologists, cosmetologists and related experimenters involved in safety testing as the clinical assessment of skin colour.
  • Human assays aiming at evaluating the irritancy and allergic potential of cosmetics take advantage to use instrumental assessments of skin colour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503462.001).
  • [ISSN] 1468-2494
  • [Journal-full-title] International journal of cosmetic science
  • [ISO-abbreviation] Int J Cosmet Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Fluhr JW, Breternitz M, Kowatzki D, Bauer A, Bossert J, Elsner P, Hipler UC: Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single-blinded exploratory in vivo study. Exp Dermatol; 2010 Aug;19(8):e9-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single-blinded exploratory in vivo study.
  • BACKGROUND: The epidermal part of the skin is the major interface between the internal body and the external environment.
  • The skin has a specific physiology and is to different degrees adapted for protection against multiple exogenous stress factors.
  • Clothing is the material with the longest and most intensive contact to human skin.
  • It plays a critical role especially in inflammatory dermatoses or skin conditions with an increased susceptibility of bacterial and fungal infections like atopic dermatitis.
  • AIM OF THE STUDY: We studied the mode of action of silver-loaded seaweed-based cellulosic fiber and performed a broad safety assessment.
  • The principal aim was to analyse the effects of wearing the textile on epidermal skin physiology in 37 patients with atopic dermatitis in a controlled, randomized single-blinded in vivo study.
  • Safety assessment of these fibres showed no detectable release of silver ions.
  • Furthermore, ex vivo assessment after 24 h application both in healthy volunteers and patients with atopic dermatitis by sequential tape stripping and subsequently raster electron microscopy and energy dispersive microanalysis analysis revealed no detectable amounts of silver in any of stratum corneum layers.

  • Genetic Alliance. consumer health - Eczema.
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645851.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Reactive Oxygen Species; 3M4G523W1G / Silver; 9004-34-6 / Cellulose
  •  go-up   go-down


95. Kim YR, Park SH, Lee JK, Jeong J, Kim JH, Meang EH, Yoon TH, Lim ST, Oh JM, An SS, Kim MK: Organization of research team for nano-associated safety assessment in effort to study nanotoxicology of zinc oxide and silica nanoparticles. Int J Nanomedicine; 2014;9 Suppl 2:3-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organization of research team for nano-associated safety assessment in effort to study nanotoxicology of zinc oxide and silica nanoparticles.
  • In order to investigate the nanotoxicology of nanoparticles (NPs), the Research Team for Nano-Associated Safety Assessment (RT-NASA) was organized in three parts and launched.
  • Each part focused on different contents of research directions: investigators in part I were responsible for the efficient management and international cooperation on nano-safety studies; investigators in part II performed the toxicity evaluations on target organs such as assessment of genotoxicity, immunotoxicity, or skin penetration; and investigators in part III evaluated the toxicokinetics of NPs with newly developed techniques for toxicokinetic analyses and methods for estimating nanotoxicity.
  • The RT-NASA study was carried out in six steps: need assessment, physicochemical property, toxicity evaluation, toxicokinetics, peer review, and risk communication.
  • During the need assessment step, consumer responses were analyzed based on sex, age, education level, and household income.
  • [MeSH-minor] Humans. Needs Assessment. Safety

  • Hazardous Substances Data Bank. ZINC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Nanomedicine. 2013;8:1083-93 [23515638.001]
  • [Cites] Toxicol Pathol. 1994 Mar-Apr;22(2):198-201 [7973368.001]
  • [Cites] Nanomedicine (Lond). 2010 Oct;5(8):1193-203 [21039197.001]
  • [Cites] Nano Lett. 2008 Jun;8(6):1649-53 [18459745.001]
  • [Cites] Risk Anal. 2004 Oct;24(5):1289-99 [15563295.001]
  • [Cites] Int J Nanomedicine. 2012;7:3081-97 [22811602.001]
  • [Cites] Nanoscale. 2013 Dec 7;5(23):11416-27 [23912904.001]
  • [Cites] Int J Nanomedicine. 2007;2(2):227-33 [17722550.001]
  • [Cites] Biomaterials. 2010 Apr;31(10):2866-73 [20053440.001]
  • (PMID = 25565821.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 7631-86-9 / Silicon Dioxide; SOI2LOH54Z / Zinc Oxide
  • [Other-IDs] NLM/ PMC4279765
  • [Keywords] NOTNLM ; nanomaterials / nanotoxicity / peer review / physicochemical property / toxicokinetics
  •  go-up   go-down


96. Roggeband R, Helmlinger G, Smith I, Wilhelm KP, Ryan CA, Gerberick GF: A skin sensitization safety assessment of a new bleach activator technology in detergent applications. Contact Dermatitis; 2002 Apr;46(4):211-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A skin sensitization safety assessment of a new bleach activator technology in detergent applications.
  • Animal testing demonstrated that NACAOBS, as a raw material, is a weak skin sensitizer.
  • Results confirmed the skin sensitization safety profile of laundry detergents containing NACAOBS, namely the absence of any reaction suggestive of contact sensitization (even under exaggerated dermal exposure conditions in a detergent matrix), and a skin compatibility profile comparable to that of current detergents.
  • Further confirmation of the skin safety profile was obtained from a successful 12-month market test of a granular detergent containing 3.6% of the new substance, during which not a single adverse skin reaction was reported.
  • It can be concluded that the likelihood of NACAOBS to induce skin sensitization or even elicit allergic reactions in consumer detergent use scenarios is negligible.
  • [MeSH-minor] Animals. Guinea Pigs. Humans. Mice. Skin Tests

  • Hazardous Substances Data Bank. SODIUM HYPOCHLORITE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12081699.001).
  • [ISSN] 0105-1873
  • [Journal-full-title] Contact dermatitis
  • [ISO-abbreviation] Contact Derm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Detergents; 0 / nonanoyl amido caproylacid oxybenzenesulfonate; DY38VHM5OD / Sodium Hypochlorite
  •  go-up   go-down


97. Johnson W Jr, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Galactomannans as Used in Cosmetics. Int J Toxicol; 2015 Jul-Aug;34(1 Suppl):35S-65S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Galactomannans as Used in Cosmetics.
  • The Cosmetic Ingredient Review Expert Panel (Panel) reviewed the safety of 16 galactomannans as used in cosmetics.
  • These ingredients are legume polysaccharides that function mostly as hair/skin-conditioning agents and viscosity-increasing agents in cosmetic products.
  • Their substantial molecular sizes suggest that skin penetration of these ingredients would be unlikely.
  • The Panel concluded that these galactomannans are safe in the present practices of use and concentration described in this safety assessment.
  • [MeSH-major] Caesalpinia / toxicity. Cassia / toxicity. Consumer Product Safety. Cosmetics / toxicity. Galactans / toxicity. Mannans / toxicity. Plant Gums / toxicity

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • Hazardous Substances Data Bank. GUAR GUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2015.
  • (PMID = 26227890.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Allergens; 0 / Cosmetics; 0 / Galactans; 0 / Irritants; 0 / Mannans; 0 / Plant Gums; 11078-30-1 / galactomannan; E89I1637KE / guar gum
  • [Keywords] NOTNLM ; cosmetics / galactomannans / safety
  •  go-up   go-down


98. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Dialkyl Malates as Used in Cosmetics. Int J Toxicol; 2015 Jul-Aug;34(1 Suppl):5S-17S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Dialkyl Malates as Used in Cosmetics.
  • The Cosmetic Ingredient Review Expert Panel (Panel) reviewed the safety of 6 dialkyl malate compounds used in cosmetics.
  • These ingredients function mostly as skin-conditioning agents-emollients.
  • The Panel reviewed relevant animal and human data related to the ingredients along with a previous safety assessment of malic acid.
  • The similar structure, properties, functions, and uses of these ingredients enabled grouping them and using the available toxicological data to assess the safety of the entire group.
  • The Panel concluded that these dialkyl maleate compounds are safe in the present practices of use and concentration as given in this safety assessment.
  • [MeSH-minor] Animals. Consumer Product Safety. Humans. Irritants / toxicity. Reproduction / drug effects

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2015.
  • (PMID = 26227891.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Irritants; 0 / Malates
  • [Keywords] NOTNLM ; cosmetics / dialkyl malates / safety
  •  go-up   go-down


99. Johnson W Jr, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety assessment of alkyl glyceryl ethers as used in cosmetics. Int J Toxicol; 2013 Sep-Oct;32(5 Suppl):5S-21S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety assessment of alkyl glyceryl ethers as used in cosmetics.
  • Alkyl glyceryl ethers function mostly as skin-conditioning agents in cosmetic products applied to the skin and hair.
  • The Cosmetic Ingredient Review expert panel reviewed the available animal toxicity and clinical data, including the low dermal absorption, and concluded that the alkyl glyceryl ethers are safe in the present practices of use and concentration described in this safety assessment.
  • [MeSH-minor] Animals. Consumer Product Safety. Cosmetics. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24174475.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Glyceryl Ethers
  • [Keywords] NOTNLM ; alkyl glyceryl ethers
  •  go-up   go-down


100. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Pentaerythrityl Tetraesters as Used in Cosmetics. Int J Toxicol; 2015 Sep;34(2 Suppl):99S-112S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Pentaerythrityl Tetraesters as Used in Cosmetics.
  • The Cosmetic Ingredient Review (CIR) Expert Panel (Panel) reviewed the safety of 16 pentaerythrityl tetraester compounds as used in cosmetics.
  • These ingredients mostly function as hair-conditioning agents, skin-conditioning agents-miscellaneous and binders, skin-conditioning agents-occlusive, viscosity-increasing agents-nonaqueous, and skin-conditioning agents-emollient.
  • The Panel reviewed the available animal and human data related to these ingredients and previous safety assessments of the fatty acid moieties.
  • The Panel concluded that pentaerythrityl tetraisostearate and the other pentaerythrityl tetraester compounds were safe in the practices of use and concentration as given in this safety assessment.
  • [MeSH-major] Consumer Product Safety. Cosmetics / adverse effects. Cosmetics / chemistry. Esters / adverse effects. Esters / chemistry. Hydrocarbons, Chlorinated / adverse effects. Hydrocarbons, Chlorinated / chemistry
  • [MeSH-minor] Humans. Risk Assessment

  • MedlinePlus Health Information. consumer health - Cosmetics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2015.
  • (PMID = 26362123.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Esters; 0 / Hydrocarbons, Chlorinated; 3228-99-7 / pentaerythrityl tetrachloride
  • [Keywords] NOTNLM ; cosmetics / pentaerythrityl tetraesters / safety
  •  go-up   go-down






Advertisement